

CTAD

2025

Clinical Trials on Alzheimer's Disease

December 1-4, 2025
San Diego, CA, United States



PRELIMINARY PROGRAM

Montpellier '08 • Las Vegas '09 • Toulouse '10 • San Diego '11 • Monte Carlo '12 • San Diego '13
Philadelphia '14 • Barcelona '15 • San Diego '16 • Boston '17 • Barcelona '18 • San Diego '19 Virtual
'20 • Boston '21 • San Francisco '22 • Boston '23 • Madrid '24

www.ctad-alzheimer.com
Email: ctad@ant-congres.com

JPAD
THE JOURNAL
OF PREVENTION
OF ALZHEIMER'S
DISEASE



TABLE OF CONTENTS

Organizing & Scientific Committees	03
Lifetime Achievement Award	04
Keynotes	05
Scientific sessions	
Monday, December 1	07
Tuesday, December 2	09
Wednesday, December 3	13
Thursday, December 4	17
Poster presentations	22

CTAD Organizing Committee and Scientific Committee

Susan ABUSHAKRA (San Francisco, United States); Paul AISEN (San Diego, United States)*; Rebecca E. AMARIGLIO (Boston, United States); Patricia ANDREWS (Nashville, United States); Sandrine ANDRIEU (Toulouse, France)*; Davide ANGIONI (Toulouse, France); Laura D. BAKER (Winston-Salem, United States); Randall J. BATEMAN (St. Louis, United States); Karim BENNYS (Montpellier, France); Ram BISHNOI (Tampa, United States); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, United States); Maria CARRILLO (Chicago, United States); Mathieu CECCALDI (Marseille, France); Suzanne CRAFT (Winston-Salem, United States); Lucia CRIVELLI (Buenos Aires, Argentina); Jeffrey CUMMINGS (Las Vegas, United States); Steven DEKOSKY (Gainesville, United States); Michael C. DONOHUE (San Diego, United States); Rachelle DOODY (Houston, United States); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, United States); Howard FILLIT (New York, United States); Nick FOX (London, UK); Kristian Steen FREDERIKSEN (Copenhagen, Denmark); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Joshua GRILL (Los Angeles, United States); Michael GRUNDMANN (San Diego, United States); Harald HAMPEL (Nutley, United States); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Jakub HORT (Prague, Czech Republic); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, United States); Zaven KHACHATURIAN (Washington DC, United States); Miia KIVIPELTO (Stockholm, Sweden); Yan LI (St. Louis, United States); Jorge J. LLIBRE GUERRA (St. Louis, United States); Constantine G. LYKETSOS (Baltimore, United States); Gad A. MARSHALL (Boston, United States); Adam MECCA (New Haven, United States); Lefkos T. MIDDLETON (London, UK)*; José Luis MOLINUEVO (Valby, Denmark); Kyra O'BRIEN (Philadelphia, United States); Claire PAQUET (Paris, France); Robert PERNECZKY (Munich, Germany); Ronald PETERSEN (Rochester, United States); Elif PINAR COSKUN (Lexington, United States); Michael S. RAFII (San Diego, United States); Rema RAMAN (San Diego, United States); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, United States); Marwan SABBAGH (Phoenix, United States); Stephen SALLOWAY (Providence, United States); Pascual SANCHEZ-JUAN (Madrid, Spain); Nikolaos SCARMEAS (New York, United States); Rachel SCHINDLER (New York, United States); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, United States); Eric SIEMERS (Indianapolis, United States); Sietske SIKKES (Amsterdam, The Netherlands); Yong SHEN (Hefei, China); Jiong SHI (Hefei, China); Irina SKYLAR-SCOTT (Stanford, United States); Heather SNYDER (Chicago, United States); Maria SOTO (Toulouse, France); Reisa SPERLING (Boston, United States)*; Yaakov STERN (New York, United States); Duygu TOSUN (San Francisco, United States); Jacques TOUCHON (Montpellier, France)*; Maileen ULEP (Las Vegas, United States); Wiesje van Der FLIER (Amsterdam, The Netherlands); Christopher H. VAN DYCK (New Haven, United States); Bruno VELLAS (Toulouse, France); Prashanthi VEMURI (Rochester, United States); Michael W. WEINER (San Francisco, United States)*; Donna M. WILCOCK (Indianapolis, United States); Bengt WINBLAD (Stockholm, Sweden); Kirsten WRIGHT (Portland, United States); Jin-Tai YU (Shanghai, China)

*Organizing Committee Member

CTAD 2025

Lifetime Achievement Award

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research, is awarded to Takeshi Iwatsubo MD, PhD in recognition for his pioneering work in Alzheimer's Disease neuroimaging and neuropathology.



Takeshi IWATSUBO

Director of the National Institute of Neuroscience, National Center of Neurology and Psychiatry, Project Professor of the University of Tokyo.

Chairman of the Japan Society for Dementia Research.

Biography

Trained as a neurologist and neuropathologist, Dr. Iwatsubo has contributed to the study of human neurodegenerative diseases, particularly Alzheimer's and Parkinson's, using multidisciplinary approaches. He demonstrated that Ab42 is the initial species deposited in senile plaque amyloid, elucidated the process of γ -secretase complex formation, and identified phosphorylated α -synuclein as a component of Lewy bodies. He was the Principal Investigator of the Japanese AD Neuroimaging Initiative (J-ADNI) and the Japanese Trial Ready Cohort for Prevention of Alzheimer's Disease (J-TRC), and currently is the PI of the Japanese Registry for AD-DMT. He is the recipient of the MetLife Award for Medical Research (2008), AAIC Lifetime Achievement Award (2010), the Potamkin Prize (2012), and the Medal with Purple Ribbon from the Japanese government (2024).

CTAD 2025

Keynotes



Next Generation Anti-Amyloid Therapies ...Shuttling Past the ARIA Risk

Ronald B. DeMattos, PhD, *Senior Vice President and Chief Scientific Officer for Neurobiology, Eli Lilly and Company – Indianapolis, IN (United States)*

Ronald B. DeMattos, Ph.D. is a Senior Vice President and Chief Scientific Officer for Neurobiology at Eli Lilly. Dr. DeMattos received his doctorate in molecular and cellular biochemistry (SUNY – Stony Brook, 1998) and performed a post-doctoral fellowship at Washington University School of Medicine (Holtzman Lab). Dr. DeMattos joined Eli Lilly in 2002 and has since held multiple scientific positions within Neuroscience Discovery over the last 20+ years. He discovered and developed numerous compounds that progressed to clinical studies in Alzheimer's disease patients, including Solanezumab, Donanemab (FDA-approved Kisunla), and Remternetug (Phase-3 ongoing). He currently leads multiple discovery projects while managing the Indianapolis Neurodegeneration Discovery group, whose mission is to develop novel first-in-class therapies for neurodegeneration and Alzheimer's disease.



Enhancing Participation of Representative Populations in Alzheimer Disease Clinical Trials

Sid O'Bryant, PhD, *Principal Investigator of the Health & Aging Brain Study, The University of North Texas Health Science Center at Fort Worth – Fort Worth, TX (United States)*

Dr. Sid O'Bryant is the principal investigator of the Health & Aging Brain Study – Health Disparities (HABS-HD), the most comprehensive study of Alzheimer's disease among the three largest racial/ethnic groups in the U.S. ever conducted: African Americans, Hispanics, and non-Hispanic whites. The goal of HABS-HD is to understand the life-course factors—including biological, sociocultural, environmental, and behavioral—that influence Alzheimer's disease risk in later life. This work aims to create population-specific precision-medicine approaches to treat and prevent Alzheimer's disease. Dr. O'Bryant is also a global expert in using blood-based biomarkers to develop precision-medicine strategies for diagnosing and treating Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease in adults with Down Syndrome.



From Real World Data to Clinical Trials: The Case for Investigating Semaglutide in Alzheimer's Disease.

Peter Johannsen, MD, PhD, *International Medical Vice President, Novo Nordisk, Copenhagen (Denmark)*

Dr. Peter Johannsen is a board-certified neurologist with more than 30 years' experience in cognitive neurology and Alzheimer's trials. He joined Clinical Drug Development at Novo Nordisk in 2020. Dr. Johannsen is scientifically responsible for Novo Nordisk's neurology development programs, including Alzheimer's disease. He previously served as senior consultant neurologist at the Memory Clinic, Rigshospitalet, and the National Danish Dementia Research Centre, Copenhagen University Hospital, Denmark, gaining extensive experience from clinical trials in Alzheimer's disease from first-in-human to Phase III. He has published over 100 scientific papers and given more than 300 lectures on Alzheimer's disease treatment. He also served as vice-chairman of the Danish Alzheimer Association and as a board member of the European Alzheimer's Disease Consortium (EADC).

Program at a glance

● Monday, December 1

- 3:45 p.m. Welcome ceremony
- 3:50 p.m. CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research
- 4:05 p.m. **Introductory Lecture:** Alzheimer's Therapeutics: Past, Present, Future
- 4:20 p.m. **KEYNOTE 1:** Enhancing Participation of Representative Populations In Alzheimer Disease Clinical Trials
- 4:45 p.m. LATE BREAKING COMMUNICATIONS
- 6:15 p.m. **SYMPOSIUM 1:** Trontinemab's path to Phase III – From proof-of-concept in the ongoing Brainshuttle™ AD study to the pivotal studies TRONTIER 1 and TRONTIER 2 in people with early-stage symptomatic Alzheimer's disease
- 7:00 p.m. CTAD WELCOME RECEPTION with the Support of the Alzheimer's Association

● Tuesday, December 2

- 7:30 a.m. POSTER WALKING TOUR
- 8:30 a.m. LATE BREAKING COMMUNICATIONS
- 9:15 a.m. **KEYNOTE 2:** From Real World Data to Clinical Trials: The Case for Investigating Semaglutide in Alzheimer's Disease.
- 9:40 a.m. ORAL COMMUNICATIONS
- 10:40 a.m. COFFEE BREAK AND POSTER SESSION
- 11:10 a.m. **SYMPOSIUM 2:** The U.S. POINTER Trial: Imaging, neurovascular, and sleep outcomes
- 11:50 a.m. LATE BREAKING COMMUNICATIONS
- 12:50 p.m. LUNCH ON YOUR OWN
- 1:30 p.m. COFFEE BREAK IN THE POSTER HALL
- 1:50 p.m. ORAL COMMUNICATIONS
- 3:20 p.m. **ROUNDTABLE 1:** Charting the Path Forward for Combination Therapy in Alzheimer's Disease: Challenges, Considerations, and Collaborative Solutions
- 4:00 p.m. COFFEE BREAK AND POSTER SESSION
- 4:30 p.m. LATE BREAKING COMMUNICATIONS
- 5:30 p.m. End of the conference day

● Wednesday, December 3

- 7:30 a.m. POSTER WALKING TOUR
- 8:30 a.m. LATE BREAKING COMMUNICATIONS
- 9:30 a.m. **KEYNOTE 3:** Next Generation Anti-Amyloid Therapies ...Shuttling Past the ARIA Risk
- 9:55 a.m. ORAL COMMUNICATIONS
- 10:55 a.m. COFFEE BREAK AND POSTER SESSION
- 11:25 a.m. ORAL COMMUNICATIONS – Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease
- 12:35 p.m. LUNCH ON YOUR OWN
- 1:15 p.m. COFFEE BREAK IN THE POSTER HALL
- 1:30 p.m. **SYMPOSIUM 3:** ALZNET: First Look at Real-World Use of Novel Alzheimer's Disease Therapies in the United States
- 2:10 p.m. LATE BREAKING COMMUNICATIONS
- 3:55 p.m. COFFEE BREAK AND POSTER SESSION
- 4:25 p.m. ORAL COMMUNICATIONS
- 5:10 p.m. **SYMPOSIUM 4:** TOPLINE RESULTS from Evoke and Evoke+: Two Phase 3 Randomized Placebo-Controlled Trials of Semaglutide in Participants with Early-Stage Symptomatic Alzheimer's Disease
- 5:50 p.m. End of the Conference Day

● Thursday, December 4

- 7:30 a.m. POSTER WALKING TOUR
- 8:30 a.m. LATE BREAKING COMMUNICATIONS
- 9:30 a.m. ORAL COMMUNICATIONS – AD CLINICAL TRIALS – PHASE 1
- 10:40 a.m. COFFEE BREAK AND POSTER SESSION
- 11:10 a.m. **SYMPOSIUM 5:** Advancing the Science of Recruitment for Preclinical Alzheimer's Disease Clinical Trials
- 11:50 a.m. ORAL COMMUNICATIONS
- 12:35 p.m. LUNCH ON YOUR OWN
- 1:20 p.m. COFFEE BREAK IN THE POSTER HALL
- 1:35 p.m. LATE BREAKING COMMUNICATIONS
- 2:20 p.m. ORAL COMMUNICATIONS
- 3:50 p.m. COFFEE BREAK AND POSTER SESSION
- 4:20 p.m. ORAL COMMUNICATIONS
- 5:35 p.m. End of the CTAD Conference

Monday, December 1

3:45 p.m.
3:50 p.m.

CTAD25 Opening Ceremony

Paul Aisen, USC-ATRI - San Diego (United States) and Jacques Touchon, Montpellier University - Montpellier (France)

3:50 p.m.
4:00 p.m.

CTAD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research

Presented to Takeshi Iwatsubo MD, PhD in recognition for his pioneering work in Alzheimer's Disease Neuroimaging and Neuropathology.

4:00 p.m.
4:20 p.m.

Introductory Lecture: Alzheimer's Therapeutics: Past, Present, Future

Paul Aisen, USC-ATRI - San Diego (United States)

4:20 p.m.
4:45 p.m.

KEYNOTE 1

Enhancing Participation of Representative Populations in Alzheimer Disease Clinical Trials

Sid O'Bryant, The University of North Texas Health Science Center at Fort Worth – Fort Worth, TX (United States)

Introduction: Howard Feldman, University of California San Diego, La Jolla (United States)

4:45 p.m.
6:00 p.m.

LATE BREAKING COMMUNICATIONS

4:45 p.m.

LB1 –

5:00 p.m.

LB2 –

5:15 p.m.

LB3 –

5:30 p.m.

LB4 –

5:45 p.m.

LB5 –

6:15 p.m.
7:00 p.m.

SYMPOSIUM 1

Trontinemab's path to Phase III – From proof-of-concept in the ongoing Brainshuttle™ AD study to the pivotal studies TRONTIER 1 and TRONTIER 2 in people with early-stage symptomatic Alzheimer's disease

Chair: Reisa Sperling, Brigham and Women's Hospital - Massachusetts General Hospital - Boston (United States)

Presentation 1: Brainshuttle™ AD: New interim results of a randomized, placebo-controlled Phase Ib/IIa proof-of-concept study with trontinemab, a novel anti-amyloid monoclonal bispecific antibody for the treatment of Alzheimer's disease

Luka Kulic, F. Hoffmann-La Roche Ltd - Basel (Switzerland)

Presentation 2: TRONTIER 1 and 2: Rationale and design of two identical Phase III trials to assess the efficacy and safety of trontinemab in early symptomatic Alzheimer's disease

Catherine Mummery, *Queen Square Institute of Neurology, UCL – London (United Kingdom)*

Presentation 3: The TRAVELLER master pre-screener protocol: An approach to reduce participant burden and broaden access to clinical trials in Alzheimer's disease

Christopher Lane, *Roche Products Ltd - Welwyn Garden City (United Kingdom)*

7:00 p.m.
8:00 p.m.

CTAD WELCOME RECEPTION with the Support of the Alzheimer's Association



Tuesday, December 2

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR

8:30 a.m.
9:15 a.m.

LATE BREAKING COMMUNICATIONS

8:30 a.m.

LB6 –

8:45 a.m.

LB7 –

9:00 a.m.

LB8 –

9:15 a.m.
9:40 a.m.

KEYNOTE 2

From Real World Data to Clinical Trials: The Case for Investigating Semaglutide in Alzheimer's Disease.

Peter Johannsen, Novo Nordisk - Copenhagen (Denmark)

Introduction: Sandrine Andrieu, IHU HealthAge & INSERM, Toulouse (France)

9:40 a.m.
10:40 a.m.

ORAL COMMUNICATIONS

9:40 a.m.

OC1 – The effect of herpes zoster vaccination at different stages of the dementia disease course: Implications for defining the study population of clinical trials

Min Xie¹, Markus Eytting¹, Christian Bommer¹, Haroon Ahmed², Pascal Geldsetzer¹

¹Stanford University - Stanford (United States), ²Cardiff University - Cardiff (United Kingdom)

9:55 a.m.

OC2 – CSF MTBR-tau243 improves prediction of longitudinal clinical progression and trial efficiency in early Alzheimer's disease

Viswanath Devanarayan¹, Todd Nelson¹, Thomas Doherty², Erica Andreozzi¹, Kristin Wildsmith¹, Pallavi Sachdev¹, Kanta Horie¹, Arnaud Charil¹, Harald Hampel¹, Lynn Kramer¹, Shobha Dhadda¹, Michael Irizarry¹

¹Eisai Inc. - Nutley (United States), ²Eisai Inc. - Hatfield (United Kingdom)

10:10 a.m.

OC3 – Biological staging of Alzheimer's disease using blood-based biomarkers

Gemma Salvadó^{1,2}, Kanta Horie^{3,4,5}, Nicholas Barthélemy^{3,4}, Suzanne E. Schindler^{4,6}, Shorena Janelidze¹, Anna Orduña Dolado¹, Divya Bali¹, Erik Stomrud^{1,7}, Niklas Mattsson-Carlsson^{1,8,9}, Sebastian Palmqvist^{1,7}, Jacob W. Vogel¹⁰, Randall J. Bateman^{3,4,6,11}, Rik Ossenkoppele^{1,12,13}, Oskar Hansson¹

¹Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), ²BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ³The Tracy Family SILQ Center, Washington University School of Medicine - St Louis (United States), ⁴Department of Neurology, Washington University School of Medicine - St Louis (United States), ⁵Eisai Inc. - Nutley (United States), ⁶Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine - St Louis (United States), ⁷Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁸Wallenberg Center for Molecular Medicine, Lund University - Lund (Sweden), ⁹Department of Neurology, Skåne University Hospital - Lund (Sweden), ¹⁰Department of Clinical Sciences Malmö, SciLifeLab, Lund University - Lund (Sweden), ¹¹Hope Center for Neurological Disorders, Washington University School of Medicine - St Louis (United States), ¹²Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands), ¹³Amsterdam Neuroscience, Neurodegeneration - Amsterdam (Netherlands)

10:25 a.m.

OC4 – The SMART-HS Study: A Targeted Therapeutic Strategy for LATE Disease

E. Pinar Coskun¹, Ahmed Bahrani¹, Lauren Bojarski¹, Justin Barber¹, Danica Coy¹, Emily Smith¹, Molly Harper¹, Alexandra Curtis¹, Erin Abner¹, Brian Gold¹, Linda Van Eldik¹, Peter Nelson¹, Gregory Jicha¹

¹University of Kentucky - Lexington (United States)

10:40 a.m.
11:10 a.m.

COFFEE BREAK AND POSTER SESSION

Tuesday, December 2

11:10 a.m.
11: 50 a.m.

SYMPOSIUM 2

The U.S. POINTER Trial: Imaging, neurovascular, and sleep outcomes

Chair: Susan Landau, UC Berkeley - Berkeley (United States)

Presentation 1: U.S. POINTER Trial Outcomes: Results of the Imaging Ancillary Study

Susan Landau, UC Berkeley - Berkeley (United States)

Presentation 2: POINTER-NV: Results of the U.S. POINTER Neurovascular Ancillary Study

Tina E. Brinkley, Wake Forest University School of Medicine - Winston-Salem (United States)

Presentation 3: POINTER-zzz: Results of the U.S. POINTER Sleep Ancillary Study

Laura D. Baker, Wake Forest University School of Medicine - Winston-Salem (United States)

11:50 a.m.
12:50 p.m.

LATE BREAKING COMMUNICATIONS

11:50 a.m.

LB9 -

12:05 p.m.

LB10 -

12:20 p.m.

LB11 -

12:35 p.m.

LB12 -

12:50 p.m.
1:30 p.m.

LUNCH ON YOUR OWN

1:30 p.m.
1:50 p.m.

COFFEE BREAK IN THE POSTER HALL

1:50 p.m.
3:20 p.m.

ORAL COMMUNICATIONS

1:50 p.m.

OC5 - The Effects of Lecanemab Treatment on Soluble CSF A β Protofibrils in Clarity AD

Kanta Horie¹, Akihiko Koyama¹, Pallavi Sachdev¹, Kazuyoshi Shuta², Kazuhiro Tahara², Michio Kanekiyo¹, Shobha Dhadda¹, Larisa Reyderman¹, Steven Hersch¹, Michael Irizarry¹, Lynn Kramer¹

¹Eisai Inc. - Nutley (United States), ²Eisai Co., Ltd. - Tsukuba (Japan)

2:05 p.m.

OC6 - Impact of a 10-Year Multidomain Lifestyle Intervention on Long-Term Risks for Cognitive Impairment: The Look AHEAD Program

Mark Espeland¹, Rebecca Neiberg¹, Haiying Chen¹, Stephen Rapp¹, Bonnie Sachs¹, Chinedu Udeh-Momoh¹, Laura Baker¹, Kathleen Hayden¹, Denise Houston¹, Jose Luchsinger², Rena Wing³, Sevil Yasar⁴, Lynne Wagenknecht¹

¹Wake Forest University School of Medicine - Winston Salem (United States), ²Columbia University Irving Medical Center - New York (United States), ³The Miriam Hospital - Providence (United States), ⁴Johns Hopkins School of Medicine - Baltimore (United States)

2:20 p.m.

OC7 - Outcomes from the BetterBrains Trial, a multi-domain, person-centred, dementia risk factor management randomised controlled trial to prevent cognitive decline

Emily Rosenich¹, Darshini Ayton¹, Stephanie Pirotta¹, Hannah Cummins¹, Maya Norfolk¹, Nawaf Yassi², Shantha Rajaratnam¹, Richard Sinnott², Matthew Pase¹, Amy Brodtmann¹, Ashley Bush³, Leonid Churilov², Anna Barker¹, Paul Maruff⁴, Yen Ying Lim¹

¹Monash University - Melbourne (Australia), ²University of Melbourne - Melbourne (Australia), ³Florey Institute - Melbourne (Australia), ⁴Cogstate Ltd - Melbourne (Australia)

Tuesday, December 2

2:35 p.m.

OC8 – Quantifying tau knockdown in individuals with Alzheimer’s Disease receiving intrathecal tau MAPT antisense oligonucleotide NI0752 using Stable Isotope Labelling Kinetics (SILK) – interim analysis of a phase 1B randomised, double-blinded, placebo-controlled, multicentre trial

Aram Aslanyan^{1,2}, Chihiro Sato^{3, 4}, Donald Elbert⁵, Catherine Mummery^{1, 2}, Nupur Ghoshal³, Eric Mcdade³, Randall Bateman^{3, 4, 6}, **Ross Paterson**^{1, 2, 4, 7}

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London - London (United Kingdom), ²National Hospital for Neurology and Neurosurgery - London (United Kingdom), ³Department of Neurology, Washington University School of Medicine in St Louis - St. Louis (United States), ⁴The Tracy Family Stable Isotope Labeling Quantitation Center, Washington University School of Medicine, Washington University in St. Louis - St. Louis (United States), ⁵Department of Neurology, University of Washington - Seattle (United States), ⁶Dominantly Inherited Alzheimer Network, Washington University in St. Louis - St. Louis (United States), ⁷Darent Valley Hospital - Dartford (United Kingdom)

2:50 p.m.

OC9: Insights into Clinical Trial Recruitment: An Analysis of Prescreening Data from the AHEAD Study

Dylan Kirn^{1,2}, Shunran Wang³, Karin Ernstrom³, Joshua D. Grill^{4,5}, Gustavo Jimenez-Maggiora³, Doris Molina-Henry³, Paul Aisen³, Reisa Sperling^{1, 2}, Rema Raman³

¹Department of Neurology, Brigham and Women’s Hospital - Boston (United States), ²Department of Neurology, Massachusetts General Hospital - Boston (United States), ³Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego (United States), ⁴Institute for Memory Impairments and Neurological Disorders, University of California Irvine - Irvine (United States), ⁵Department of Psychiatry and Human Behavior, University of California Irvine - Irvine (United States)

3:05 p.m.

OC10: Results from the open-label extension period of TOGETHER, a Phase II study evaluating efficacy, safety and tolerability of bepranemab in prodromal–mild Alzheimer’s disease

William Byrnes¹, Irene Rebollo Mesa², Tim Buchanan³, Bart Van Den Steen³, Hans Van Tricht³, Katie Taiyari⁴, Omobola Famodimu⁵, Jos Bloemers⁶, **Saori Shimizu**⁷, Ute Massow⁸, Ralph P. Maguire³, Colin Ewen⁴

¹UCB - Raleigh (United States), ²UCB - Madrid (Spain), ³UCB - Braine-L’alleud (Belgium), ⁴UCB - Slough (United Kingdom), ⁵UCB - Oakville (Canada), ⁶UCB - Breda (Netherlands), ⁷UCB - Brussels (Belgium), ⁸UCB - Monheim Am Rhein (Germany)

3:20 p.m.

4:00 p.m.

ROUNDTABLE 1

Charting the Path Forward for Combination Therapy in Alzheimer’s Disease: Challenges, Considerations, and Collaborative Solutions

Chair: Howard Fillit, Alzheimer’s Drug Discovery Foundation - New York City (United States)

Presentation 1: Add-On Combination Therapy with Monoclonal Antibodies: Implications for Drug Development

Jeffrey Cummings, Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, UNLV - Las Vegas, (United States)

Presentation 2: Considerations in the Development and Use of Biomarkers for Combination Therapy in Alzheimer’s Disease

Suzanne Schindler, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine – St. Louis (United States)

Presentation 3: Regulatory Perspective on Future Combination Trials

-

Discussion: Jeffrey Cummings (Moderator)¹, Suzanne Schindler², Howard Fillit³, Szofia Bullain⁴

¹Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada at Las Vegas, Las Vegas, NV, United States; ²Department of Neurology, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO, United States; ³Alzheimer’s Drug Discovery Foundation, New York, NY, United States; ⁴Biogen, Cambridge, MA, United States.

● Tuesday, December 2

4:00 p.m.

4:30 p.m.

COFFEE BREAK AND POSTER SESSION

4:30 p.m.

5:45 p.m.

LATE BREAKING COMMUNICATIONS

4:30 p.m.

LB13 –

4:45 p.m.

LB14 –

5:00 p.m.

LB15 –

5:15 p.m.

LB16 –

5:30 p.m.

LB17 –

5:45 p.m.

6:15 p.m.

ROUNDTABLE 2
CTAD China Clinical Trials Initiative

6:15 p.m.

END OF THE CONFERENCE DAY

● Wednesday, December 3

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR

8:30 a.m.
9:30 a.m.

LATE BREAKING COMMUNICATIONS

8:30 a.m.

LB18 –

8:45 a.m.

LB19 –

9:00 a.m.

LB20 –

9:15 a.m.

LB21 –

9:30 a.m.
9:55 a.m.

KEYNOTE 3

Next Generation Anti-Amyloid TherapiesShuttling Past the ARIA Risk

Ronald B. DeMattos, *Eli Lilly and Company – Indianapolis, IN (United States)*

Introduction: **Reisa Sperling**, *Brigham and Women's Hospital - Massachusetts General Hospital - Boston (United States)*

9:55 a.m.
10:55 a.m.

ORAL COMMUNICATIONS

9:55 a.m.

OC11: Combining endogenous CSF MTBR-tau243 and plasma pTau217 enhances prediction of continuous regional tau PET burden in amyloid-positive early Alzheimer's disease

Viswanath Devanarayan¹, Thomas Doherty², Erica Andreozzi¹, Kristin Wildsmith¹, Pallavi Sachdev¹, Kanta Horie¹, Arnaud Charil¹, Harald Hampel¹, Lynn Kramer¹, Shobha Dhadda¹, Michael Irizarry¹

¹Eisai Inc. - Nutley (United States), ²Eisai Inc. - Hatfield (United Kingdom)

10:10 a.m.

OC12: Brain volume changes with gantenerumab: relationship with amyloid removal

Matteo Tonietto¹, Erica Silvestri^{1,2}, Christopher Belder^{3,4}, Frederik Barkhof^{3,5}, Nick Fox³, Janice Smith⁶, Gregory Klein¹

¹Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²A*P Consulting Ltd - Sandwich (United Kingdom), ³Dementia Research Centre, UCL Queen Square Institute of Neurology - London (United Kingdom), ⁴Department of Neurology, Royal Adelaide Hospital and Queen Elizabeth Hospital - Adelaide (Australia), ⁵Department of Radiology & Nuclear Medicine - Amsterdam (Netherlands), ⁶Roche Products Ltd - Welwyn Garden City (United Kingdom)

10:25 a.m.

OC13: Head-to-head comparison of SWI and T2*-weighted gradient echo MRI sequences to detect ARIA-H in the TRAILBLAZER-ALZ 6 trial of donanemab

Diana Svaldi¹, Alessandro Biffi¹, Hong Wang¹, Emel Serap Nery¹, Chuning Gao¹, Ming Lu¹, Emily Collins¹, Karolina Feakins¹, Sergey Shcherbinin¹, Dawn Brooks¹, John Sims¹

¹Eli Lilly and Company - Indianapolis (United States)

10:40 a.m.

OC14: Longitudinal trajectories of plasma p tau217 in cognitively unimpaired older adults using a fully automated platform

Marisa N. Denkinger¹, Sterling C. Johnson², Alpana Singh¹, Taina Marques¹, Rachael E. Wilson², Ramiro E. Rea Ryes², Antoine Leuzi¹, Valentina Ghisays³, Robert C. Alexander³, Reisa A. Sperling⁴, Keith A. Johnson⁵, Paul A. Aisen⁶, Jessica B. Langbaum³, Eric M. Reiman³, Nicholas J. Ashton³

¹Banner Sun Health Research Institute - Sun City (United States), ²Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison - Madison (United States), ³Banner Alzheimer's Institute - Phoenix (United States), ⁴Department of Neurology, Massachusetts General Hospital, Harvard Medical School, - Boston (United States), ⁵Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital - Boston (United States), ⁶Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)

10:55 a.m.
11:25 a.m.

COFFEE BREAK AND POSTER SESSION

● Wednesday, December 3

11:25 a.m.
12:35 p.m.

ORAL COMMUNICATIONS – Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease Introduction by Chair: Howard Fillit, Alzheimer's Drug Discovery Foundation, New York, NY (United States)

11:35 a.m.

OC15: Protein-based Diagnosis and Analysis of Co-pathologies Across Neurodegenerative Diseases: Large-Scale AI-Boosted CSF and Plasma Proteomic Classifier

Ying Xu^{1,2}, Daniel Western^{1,2}, Gyu Jin Heo^{1,2}, Kwangsik Nho³, Hamilton Oh⁴, Yike Chen^{1,2}, Menghan Liu^{1,2}, Katherine Gong¹, Agustín Ruiz^{5,2}, María Victoria Fernández^{6,1}, David Bennett^{7,6,8}, Tony Wyss-Coray⁹, Muhammad Ali^{1,2}, Carlos Cruchaga^{1,2}
¹Department of Psychiatry, Washington University School of Medicine - St. Louis (United States), ²NeuroGenomics and Informatics Center, Washington University School of Medicine - St. Louis (United States), ³Indiana University School of Medicine - Indianapolis (United States), ⁴Icahn School of Medicine at Mount Sinai - New York (United States), ⁵Ace Alzheimer Center Barcelona - Barcelona (Spain), ⁶CIBERNED, National Institute of Health Carlos III - Madrid (Spain), ⁷Rush Alzheimer's Disease Center, Rush University Medical Center - Chicago (United States), ⁸Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, - San Antonio (United States), ⁹Wu Tsai Neurosciences Institute, Stanford University - California (United States)

11:50 a.m.

OC16: Identifying and stratifying Alzheimer's disease using circular RNA biomarkers in blood

Bridget Phillips^{1, 2, 3}, Jessie Sanford^{1, 2, 3}, Devin Dikec^{1, 2, 3}, Menghan Liu^{1, 2, 3}, Matt Johnson^{1, 2, 3}, John Budde^{1, 2, 3}, John Morris^{4, 5, 6}, Nikolaos Mellios⁷, Alison Goate⁸, Alan Renton⁸, Dominantly Inherited Alzheimer Network Consortia⁹, Richard Perrin^{4, 5, 6}, Laura Ibanez^{1, 2, 4}, Carlos Cruchaga^{2, 1, 3}
¹Department of Psychiatry, Washington University School of Medicine - St. Louis (United States), ²NeuroGenomics and Informatics Center, Washington University School of Medicine - St. Louis (United States), ³Hope Center for Neurological Disorders, Washington University School of Medicine - St. Louis (United States), ⁴Department of Neurology, Washington University School of Medicine - St. Louis (United States), ⁵Department of Pathology and Immunology, Washington University School of Medicine - St. Louis (United States), ⁶Knight Alzheimer Disease Research Center, Washington University School of Medicine - St. Louis (United States), ⁷Circular Genomics Inc - San Diego (United States), ⁸Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai - New York (United States), ⁹Dominantly Inherited Alzheimer Network (DIAN) - St. Louis (United States)

12:05 p.m.

OC17: Large-scale Plasma Proteomic Profiling Unveils Diagnostic Biomarkers and Pathways for Alzheimer's Disease

Heo Gyu Jin¹, Ying Xu¹, Jigyasha Timsina¹, Daniel Western¹, Carlos Cruchaga¹
¹Washington University - Saint Louis (United States)

12:20 p.m.

OC18: Biomarkers Associated with Response to Treatment of Early Stage AD with Pepinemab, Anti-SEMA4D Blocking Antibody

Maurice Zauderer¹, Elizabeth Evans¹, Terrence Fisher¹, Vikas Mishra¹, Leslie Balch¹, Elaine Gersz¹, John Leonard¹, Crystal Mallow¹, Anton Porsteinsson², Raymond Turner³, John Huffaker⁴
¹Vaccinex, Inc. - Rochester (United States), ²University of Rochester - Rochester (United States), ³Georgetown University - Washington, Dc (United States), ⁴Neuropsychiatric Research Center - Southwest Florida (United States)

12:35 p.m.
1:15 p.m.

LUNCH ON YOUR OWN

1:15 p.m.
1:30 p.m.

COFFEE BREAK IN THE POSTER HALL

1:30 p.m.
2:10 p.m.

SYMPOSIUM 3

ALZNET: First Look at Real-World Use of Novel Alzheimer's Disease Therapies in the United States

Chair: Reisa Sperling, Brigham and Women's Hospital - Massachusetts General Hospital - Boston (United States)

Presentation 1: ALZNET: An Update on Registry Growth and Collaborations

Maria C. Carrillo, Alzheimer's Association - Chicago (United States) on behalf of the ALZ-NET Study Team

Presentation 2: The ALZ-NET patient population: Demographics, Genetics and Biomarker Testing

Gil D. Rabinovici, Memory and Aging Center, UCSF - San Francisco (United States) on behalf of the ALZ-NET Study Team

Presentation 3: Longitudinal assessment of clinical and safety outcomes in participants receiving beta-amyloid targeting monoclonal antibodies: Real world therapy data from ALZ-NET

Michael S. Rafii, USC-ATRI - San Diego (United States) on behalf of the ALZ-NET Study Team

● Wednesday, December 3

2:10 p.m.
2:50 p.m.

LATE BREAKING SYMPOSIUM 1

–

2:50 p.m.
3:50 p.m.

LATE BREAKING COMMUNICATIONS

2:50 p.m.

LB22 –

3:05 p.m.

LB23 –

3:20 p.m.

LB24 –

3:35 p.m.

LB25 –

3:50 p.m.
4:20 p.m.

COFFEE BREAK AND POSTER SESSION

4:20 p.m.
5:05 p.m.

ORAL COMMUNICATIONS

4:20 p.m.

OC19: Alpha-Synuclein Detection: A Versatile EV-Based Plasma Assay for Detecting Modified α -Synuclein in Synucleinopathies Without Pre-Enrichment

Carine Lim¹, Hui Ling Ko¹, Brian Minie¹, Nicole Tsang¹, Nicholas Ho¹, Huilin Shao¹, Richard Batrla²

¹Sunbird Bio - Singapore (Singapore), ²Sunbird Bio - Cambridge (United States)

4:35 p.m.

OC20: Population characteristics and implications of implementation strategies for blood-based biomarkers in Alzheimer's disease across healthcare settings: Insights from a prospective, global, multicenter study

Imke Kirste¹, Sayuri Hortsch², Craig Ritchie^{3,4}, Jeffery L. Dage^{5,6,7}, Kristian Steen Frederiksen^{8,9}, Marc Suárez-Calvet^{10,11,12}, Marwan N. Sabbagh¹³, Clara Quijano-Rubio¹⁴

¹Roche Diagnostics Solutions - Indianapolis (United States), ²Roche Diagnostics GmbH - Penzburg (Germany), ³Scottish Brain Sciences - Edinburgh (United Kingdom), ⁴Department of Medicine, University of St Andrews - St Andrews (United Kingdom), ⁵Department of Neurology, Indiana University School of Medicine - Indianapolis (United States), ⁶Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine - Indianapolis (United States), ⁷Stark Neurosciences Research Institute, Indiana University School of Medicine - Indianapolis (United States), ⁸Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital - Rigshospitalet - Copenhagen (Denmark), ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen - Copenhagen (Denmark), ¹⁰BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ¹¹Hospital del Mar Research Institute - Barcelona (Spain), ¹²Servei de Neurologia, Hospital del Mar - Barcelona (Spain), ¹³Department of Neurology, Barrow Neurological Institute - Phoenix (United States), ¹⁴Roche Diagnostics International Ltd - Rotkreuz (Switzerland)

4:50 p.m.

OC21: Donanemab in Early Symptomatic Alzheimer's Disease: Additional Insights from the TRAILBLAZER-ALZ 2 Long-Term Extension

Jennifer Zimmer

Eli Lilly and Company - Indianapolis (United States)

● Wednesday, December 3

5:05 p.m.

5:45 p.m.

SYMPOSIUM 4

TOPLINE RESULTS from Evoke and Evoke+: Two Phase 3 Randomized Placebo-Controlled Trials of Semaglutide in participants with Early-Stage Symptomatic Alzheimer's Disease

Jeffrey L. Cummings¹, Alireza Atri^{2, 3, 4}, Howard H. Feldman⁵, Mary Sano^{6, 7}, Wiesje Van Der Flier^{8, 9}, Henrik Zetterberg¹⁰, Filip K. Knop¹¹, Peter Johannsen¹¹, Teresa León¹¹, Rikke Mortensen Abschneider¹¹, Philip Scheltens^{12, 13}

¹Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas - Las Vegas (United States), ²Banner Sun Health Research Institute - Sun City (United States),

³Banner Alzheimer's Institute, - Phoenix (United States), ⁴Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ⁵Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California San Diego - La Jolla (United States), ⁶Icahn School of Medicine at Mount Sinai - New York (United States), ⁷James J Peters, VAMC - Bronx (United States), ⁸Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), ⁹Amsterdam Neuroscience, Neurodegeneration, - Amsterdam (Netherlands), ¹⁰Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg - Mölndal (Sweden), ¹¹Novo Nordisk A/S - Copenhagen (Denmark), ¹²Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam - Amsterdam Umc (Netherlands), ¹³EQT Life Sciences - Amsterdam (Netherlands)

¹¹Novo Nordisk A/S - Copenhagen (Denmark), ¹²Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam - Amsterdam Umc (Netherlands), ¹³EQT Life Sciences - Amsterdam (Netherlands)

¹²Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam - Amsterdam Umc (Netherlands), ¹³EQT Life Sciences - Amsterdam (Netherlands)

¹³EQT Life Sciences - Amsterdam (Netherlands)

5:45 p.m.

END OF THE CONFERENCE DAY

● Thursday, December 4

7:30 a.m.

POSTER WALKING TOUR

8:30 a.m.

LATE BREAKING COMMUNICATIONS

8:30 a.m.

9:30 a.m.

LB26 –

8:30 a.m.

8:45 a.m.

LB 27 –

9:00 a.m.

LB28 –

9:15 a.m.

LB29 –

9:30 a.m.

ORAL COMMUNICATIONS – AD CLINICAL TRIALS – PHASE 1 SESSION

10:40 a.m.

9:30 a.m.

OC22: A first-in-human double-blind, placebo-controlled, multiple ascending dose phase 1 study evaluating the safety and pharmacokinetics of PRX005/BMS-986446, a novel anti-MTBR tau monoclonal antibody, in healthy adults and patients with Alzheimer's disease

David P. Walling¹, Ferenc Martenyi², Brian Campbell², Jun Lee², Philip Dolan², Donna Masterman², Chad Swanson², Mark Thomas³, Min Chen³, Aditi Shahane³, Nicholas Colletti³, Nanette Hock³, Ilena George³

¹CenExel - Los Alamitos (United States), ²Prothena - Brisbane (United States), ³Bristol Myers Squibb - Princeton (United States)

9:38 a.m.

OC23: First-in-Human Study of ADEL-Y01, a Monoclonal Antibody Targeting Acetylated Tau (acK280) in the MTBR: Safety and Pharmacokinetics in Healthy Adults and Early Alzheimer's Disease

Min-Seok Kim^{1,2}, Yuna Oh¹, Sungsil Lee³, Kyung-Hoon Hwang¹, Young-Soo Sohn¹, Dong-Sik Jung³, Taeyoung Yoon³, Peter J. Winkle⁴, Seung-Yong Yoon^{1,2}

¹ADEL Institute of Science & Technology (AIST), ADEL, Inc. - Seoul (Republic of Korea), ²Department of Brain Science, Asan Medical Center, University of Ulsan College of Medicine - Seoul (Republic of Korea), ³Oscotec Inc. - Gyeonggi-Do (Republic of Korea), ⁴CenExel ACT - Anaheim (United States)

9:46 a.m.

OC24: Amyloid-related imaging abnormalities in an ongoing Phase 1 study of mivelsiran, an investigational RNA interference therapeutic targeting amyloid precursor protein, in patients with Alzheimer's disease

Neal S. Parikh¹, Sharon Cohen², Sandeep Chaudhari¹, Lynn Farugia¹, Andrew H. Ahn¹, Julia Shirvan¹, Steven M. Greenberg³

¹Alnylam Pharmaceuticals, Inc. - Cambridge (United States), ²Toronto Memory Program - Toronto (Canada), ³Harvard Medical School, Massachusetts General Hospital - Boston (United States)

9:54 a.m.

OC25: Results of a Phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of ascending single IV doses of VY7523, a tau-targeting therapeutic, in healthy adult participants

Elena Ratti¹, **Monroe Butler¹**, Naomi Muse¹, Sarah Piantedosi¹, Thrusha Chauhan¹, Beth Mellen¹, Joydip Kundu¹, Vik Arora¹, Albenia Patroneva², Maurice Emery², Raj Rajagovindan¹, Toby Ferguson¹, Alfred Sandrock¹

¹Voyager Therapeutics - Lexington (United States), ²Voyager Therapeutics Contractor - Lexington (United States)

10:02 a.m.

OC26: ABCA1-agonist treatment by CS6253 and effects on plasma total and isoform-specific apolipoprotein E in elderly men and women.

Jan Johansson¹, Bengt Winblad², Henrik Zetterberg³, Jeffrey Cummings⁴, Dobrin Nedelkov⁵, Hussein Yassine⁶

¹Artery Therapeutics, Inc. - San Ramon (United States), ²Karolinska - Stockholm (Sweden), ³Sahlgrenska - Gothenburg (Sweden), ⁴U of Nevada - Las Vegas (United States), ⁵Isoformix Inc. - Sugarland (United States), ⁶USC - Los Angeles (United States)

● Thursday, December 4

10:10 a.m.

OC27: Efficacy and safety of xanomeline and trospium chloride for cognitive impairment in Alzheimer's disease (MINDSET-1 and MINDSET-2)

Jeffrey L. Cummings¹, William P. Horan^{2,3}, Dongmei Liu³, Jessica Stanek³, Codrin Lungu³

¹University of Nevada - Las Vegas (United States), ²University of California - Los Angeles (United States), ³Bristol Myers Squibb - Princeton (United States)

10:18 a.m.

OC28: SToMP and STAMINA Clinical Trials of Senolytics in Alzheimer's Disease Treatment and Prevention

Miranda E. Orr, Washington University in St Louis - St. Louis (United States)

10:26 a.m.

OC29: Pleiotropic Effects of the CNS-Selective M1 Muscarinic Agonist NSC001: From Rapid Symptomatic Relief to Long-Term Disease Modification in Alzheimer's Disease (AD)

Manfred Windisch¹, Abraham Fisher²

¹NSC-Therapeutics GmbH - St. Radegund (Austria), ²ADPD - Holon (Israel)

10:40 a.m.

11:10 a.m.

COFFEE BREAK AND POSTER SESSION

11:10 a.m.

11:50 a.m.

SYMPOSIUM 5

Advancing the Science of Recruitment for Preclinical Alzheimer's Disease Clinical Trials

Chair: Paul Aisen, USC-ATRI - San Diego (United States)

Presentation 1: Impact of upcoming FDA enrollment requirements on recruitment for Alzheimer's disease clinical trials

Lowell Schiller, Schaeffer Institute for Public Policy & Government Service – Washington, DC (United States)

Presentation 2: Recruitment and screening in TRAILBLAZER-ALZ 3: A decentralized study of donanemab in preclinical Alzheimer's disease

Karen C. Holdridge, Eli Lilly & Company – Indianapolis (United States)

Presentation 3: Building a scalable and efficient recruitment funnel for preclinical Alzheimer's disease: The AHEAD 3-45 model

Rema Raman, USC-ATRI, San Diego (United States)

11:50 a.m.

12:35 p.m.

ORAL COMMUNICATIONS

11: 50 a.m.

OC30: Interim analysis of post-marketing observational study of lecanemab in Japan

Iwata Atsushi¹, Sakata Yukinori², Koizumi Kinuyo², Endo Akira², Kuang Weijie², Sumitomo Kenta², Ishii Mika²

¹Tokyo Metropolitan Institute for Geriatrics and Gerontology - Tokyo (Japan), ²Eisai Co., Ltd. - Tokyo (Japan)

12:05 p.m.

OC31: Completion of a Phase 2 trial evaluating safety and efficacy of the synaptic regenerative small molecule SPG302 in participants with mild-to-moderate Alzheimer's disease

Bruce Brew¹, Lauren Priest², Aimee Cazyer², Valerie Bramah³, Peter Vanderklisch⁴, Craig Erickson⁴, Sharron Gargosky⁴, Stella Saraff⁴

¹St Vincent's Hospital Sydney - Darlinghurst Nsw (Australia), ²Flinders Medical Centre - Bedford Park Sa (Australia), ³Flinders Medical Centre - Darlinghurst Nsw (Australia), ⁴Spinogenix - Los Angeles (United States)

● Thursday, December 4

12:20 p.m.

OC32: Breaking barriers in early Alzheimer's disease diagnosis: The power of the in vitro diagnostic Elecsys pT181p immunoassay in a population reflective of real-world clinical practice

Sayuri Hortsch¹, David Caley², Patrick Menzel¹, Christopher Rowe³, Mark Rapp⁴, Dag Aarlsand⁵, Anna D Burke⁶, Clara Quijano-Rubio⁷

¹Roche Diagnostics GmbH - Penzberg (Germany), ²Roche Diagnostics Limited - Burgess Hill (United Kingdom), ³Australian Dementia Network Ltd - Melbourne (Australia), ⁴Berman Clinical - New York (United States), ⁵Kings College Hospital - London (United Kingdom), ⁶Barrow Neurological Institute - Phoenix (United States), ⁷Roche Diagnostics International Ltd - Rotkreuz (Switzerland)

12:35 p.m.
1:20 p.m.

LUNCH ON YOUR OWN

1:20 p.m.
1:40 p.m.

COFFEE BREAK IN THE POSTER HALL

1:40 p.m.
2:20 p.m.

LATE BREAKING SYMPOSIUM 2

–

2:20 p.m.
3:50 p.m.

ORAL COMMUNICATIONS

2:20 p.m.

OC33: Effects of Semaglutide on Alzheimer's Disease-Related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer's Disease After 12 Weeks of Treatment

Kristian Steen Frederiksen^{1,2}, Marie Aare Bentsen³, Dylan Mathew Belmont-Rausch³, Lisbeth Carstensen³, Brian Cutler⁴, Redwan Farooq⁴, Lea Hildebrandt³, Martí Jiménez-Mausbach³, Peter Johannsen³, Gabriel Martino³, Joseph Poley-Wolf³, Amaya Zaratiegui³, Giovanni B Frisoni^{5,6}, Kathrine E Attfield⁴, Lotte Bjerre Knudsen³

¹Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital - Rigshospitalet - Copenhagen (Denmark), ²Department of Clinical Medicine, University of Copenhagen - Copenhagen (Denmark), ³Novo Nordisk - Copenhagen (Denmark), ⁴Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford - Oxford (United Kingdom), ⁵Geneva Memory Center, Geneva University Hospitals - Geneva (Switzerland), ⁶Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva - Geneva (Switzerland)

2:35 p.m.

OC34: The MultiTEP-based vaccine, AV-1959R, safely elicits high concentrations of antibodies specific to Aβ42 protofibrils/fibrils/plaques in vaccinated healthy volunteers.

Michael Agadjanyan¹, Lon Schneider², Alex Grinberg³, Anahit Ghochikyan⁴

¹Nuravax, Inc./Institute for Molecular Medicine - Irvine (United States), ²USC Keck School of Medicine - Los Angeles (United States), ³Arvax, Inc. - Adelaide (Australia), ⁴Institute for Molecular Medicine/Nuravax, Inc. - Huntington Beach (United States)

2:50 p.m.

OC35: Clinical Performance of the Elecsys CSF pTau181/Aβ42 Ratio for Concordance with Tau-PET in Two Independent Cohorts

Ruben Smith¹, Leslie Shaw², Sebastian Palmqvist¹, Niklas Mattsson-Carlgrén¹, Gregory Klein³, Matteo Tonietto³, Clara Quijano-Rubio⁴, Christopher M. Rank⁵, Myrto Andreadou⁴, Samantha C. Burnham⁶, Erik Stomrud¹

¹Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden Memory Clinic, Skåne University Hospital, Malmö, Sweden - Lund, Malmö (Sweden), ²Department of Pathology and Laboratory Medicine and the PENN Alzheimer's Disease Research Center, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, PA, United States - Philadelphia (United States), ³Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland - Basel (Switzerland), ⁴Roche Diagnostics International Ltd, Rotkreuz, Switzerland - Rotkreuz (Switzerland), ⁵Roche Diagnostics GmbH, Penzberg, Germany - Penzberg (Germany), ⁶Eli Lilly and Company, Indianapolis, IN, United States - Indianapolis (United States)

3:05 p.m.

OC36: Biomarkers of Cognitive Performance in Alzheimer's Disease in Adults with Down Syndrome

Jason Russell¹, Zinayida Schlachetzki¹, Alexander Conley², Brian Boyd², Paul Newhouse², Michael Rafii¹

¹Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), ²Center for Cognitive Medicine, Vanderbilt University Medical Center - Nashville (United States)

● Thursday, December 4

3:20 p.m.

OC37: The associations between cognitive deficits and the location of tau tangles and their consistency across clinical and observational datasets

Xingjian Zhang¹, Ritobrato Datta¹, Maggie Fedgchin², Jennifer Bogert³, Janice Wong⁴, David Henley², Gayle Wittenberg², Ziad S. Saad¹

¹Johnson & Johnson - San Diego (United States), ²Johnson & Johnson - Titusville (United States), ³Johnson & Johnson, NJ - Raritan (United States), ⁴Johnson & Johnson - Cambridge (United States)

3:35 p.m.

OC38: Strategies for Increased Representation in Trials from The NIA Health and Aging Brain Study

Charisse Winston, University of Southern California - San Diego (United States)

3:50 p.m.

COFFEE BREAK AND POSTER SESSION

4:20 p.m.

4:20 p.m.

ORAL COMMUNICATIONS

5:50 p.m.

4:20 p.m.

OC39: Estimated budget impact of a screening and treatment program for preclinical Alzheimer's disease in the U.S. over 15 years

Soeren Mattke¹, Jiahe Chen¹, Eric Reiman²

¹University of Southern California - Los Angeles (United States), ²Banner Alzheimer's Institute - Phoenix (United States)

4:35 p.m.

OC40: Long-Term Nicotine Treatment of Mild Cognitive Impairment: The MIND Trial

Paul Newhouse¹, Rema Raman², Brenda Armenta², Michael C. Donohue², Michael S. Rafii², Robert A. Rissman², Edward Levin³, Kenneth Kellar⁴, Andrew Saykin⁵, Julie Dumas⁶, Patricia Andrews¹, Rachel Tyndale⁷, Brian Boyd¹, Paul Aisen²

¹Vanderbilt University Medical Center - Nashville (United States), ²University of Southern California - San Diego (United States), ³Duke University - Durham (United States), ⁴Georgetown University - Washington, Dc (United States), ⁵Indiana University - Indianapolis (United States), ⁶University of Vermont - Burlington (United States), ⁷University of Toronto - Toronto (Canada)

4:50p.m.

OC41: Impact of Nutrition, Sleep and Physical Activity on Preservation of Intellectual Function in Older Frailty Adults (INSPIOR): A Randomized Controlled Trial

Sakurai Keisuke¹, Izumi Shiraishi¹, Ryo Tanaka¹, Miwa Watanabe¹, Momoko Funakawa¹, Saori Shimada¹, Tomoko Kawaura¹, Toshiyuki Nomura², Fuka Aoki³, Takashi Matsumoto³, Yukihiro Sugawara³, Hiroki Kayama⁴, Joseph Ledsam⁴, Shin'ichi Warisawa¹, Tatsuhiko Hisatsune¹

¹The University of Tokyo - Kashiwa (Japan), ²Mitsui Fudosan, Co., Ltd. - Kashiwa (Japan), ³NH Foods Ltd. - Tsukuba (Japan), ⁴Google - Tokyo (Japan)

5:05 p.m.

OC42: Mapping the Pathogenesis of Alzheimer's Disease in Down Syndrome: Imaging, Fluid Biomarkers, Cognition, and Sex Differences for Clinical Trial Design

Nazek Queder¹, Iris Chiang¹, Andrew Luu¹, Elizabeth Andrews¹, David Keator², Jenna N. Adams³, Lisa Taylor³, Michael Yassa³, Craig Stark³, Mark Mapstone⁴, Elizabeth Head¹

¹Department of Pathology & Laboratory Medicine, University of California, Irvine - Irvine (United States), ²Department of Psychiatry and Human Behavior, University of California, Irvine - Irvine (United States), ³University of California, Irvine - Irvine (United States), ⁴Department of Neurology, University of California, Irvine - Irvine (United States)

5:20 p.m.

OC43: Considerations for Phase 2 Trials of an A β Vaccine, AV-1959R, for Secondary Prevention of Alzheimer's Disease

Lon Schneider¹, Michael Agadjanyan², Anahit Ghochikyan²

¹Keck School of Medicine of USC - Los Angeles (United States), ²Institute for Molecular Medicine - Huntington Beach (United States)

● Thursday, December 4

5:35 p.m.

OC44: Tau positron emission tomography harmonization using the CenTauR approach: general conversion equations and external validation

Alexis Moscoso^{1,2}, Antoine Leuzy^{1,3}, Lau Raket Lars⁴, Victor L. Villemagne^{5,6}, Gregory Klein⁷, Matteo Tonietto⁷, Emily Olafson⁸, Ruben Smith^{9,10}, Fang Xie¹¹, Hartmuth Kolb³, Nadine Tatton¹, Yashmin Karten¹, Christopher C. Rowe^{12,13}, Oskar Hansson^{9,10}, Vincent Doré^{12,14}

¹Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path Institute - Tucson (United States), ²Nuclear medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n - Santiago De Compostela (Spain), ³Enigma Biomedical Group - Knoxville (United States), ⁴Eli Lilly and Company - Indianapolis (United States), ⁵Department of Psychiatry, University of Pittsburgh School of Medicine - Pittsburgh (United States), ⁶Department of Molecular Imaging & Therapy, Austin Health - Victoria (Australia), ⁷F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁸Clinical Imaging Group, Genentech, Inc. - , South San Francisco (United States), ⁹Clinical Memory Research Unit, Department of Clinical Sciences, Lund University - Lund (Sweden), ¹⁰Memory Clinic, Skåne University Hospital - Malmö (Sweden), ¹¹Department of Nuclear Medicine & PET Center, Huashan Hospital, University - Shanghai (China), ¹²Florey Department of Neuroscience, University of Melbourne - Victoria (Australia), ¹³The Australian Dementia Network (ADNeT), The University of Melbourne - Victoria (Australia), ¹⁴Health and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO - Victoria (Australia)

5:50 p.m.

END OF THE CTAD CONFERENCE

POSTER LIST

01. Clinical Trials: Methodology	23
02. Clinical Trials: Results	25
03. Clinical Trials: Imaging	27
04. Clinical Trials: Biomarkers Including Plasma	29
05. Clinical Trials: Cognitive and Functional Endpoints	33
06. Cognitive Assessment and Clinical Trials	35
07. Behavioral Disorders and Clinical Trials	36
08. Health Economics and Clinical Trials	36
09. Epidemiology and Clinical Trials	37
10. Animal Model and Preclinical Trials in AD	39
11. New Therapies and Clinical Trials	40
12. Proof of Concept for Alzheimer Drug Development Interventions	43
13. Translational Research	44
14. Beyond Amyloid and Tau	45
15. Clinical Trials Early Career Investigator Showcase	46
16. Digital Health/E-trials	47
17. Artificial Intelligence in AD Clinical Trials	49

01 ● CLINICAL TRIALS: METHODOLOGY

00283 - Improving insights on disease modification in Alzheimer's disease by including sequential GSTs in the analysis hierarchy

Presenter: Joshua Christensen

Joshua CHRISTENSEN, Daniel SMITH, Kent HENDRIX, Craig MALLINCKRODT, Suzanne HENDRIX, Samuel DICKSON

¹Pentara Corporation, Millcreek, United States

00074 - ALTITUDE-AD: Recruitment strategies for a global phase 2 trial of sabirnetug in early Alzheimer's disease

Presenter: Robyn Moxon

Robyn MOXON ¹, Alyssa CARROLL ¹, Todd FEASTER ¹, Kathy MARCOZZI PIERCE ¹, Maddelyn HYLAND ¹, Siew TIN GAN ¹, Dung TRINH ², Eric SIEMERS ¹

¹Acumen Pharmaceuticals, Inc, Newton, Massachusetts, United States, ²Healthy Brain Research, Long Beach, California, United States

00158 - Study Design of a Multiple Ascending Intravenous Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics of VY7523 in Participants with Early Alzheimer's Disease

Presenter: Monroe Butler

Monroe BUTLER ¹, Naomi MUSE ¹, Sarah PIANTEDOSI ¹, Thrusha CHAUHAN ¹, Beth MELLEN ¹, Charlotte CHUNG ¹, Raj RAJAGOVINDAN ¹, Vik ARORA ¹, Albenia PATRONEVA ², Maury EMERY ², Alfred SANDROCK ¹, Toby FERGUSON ¹, Elena RATTI ¹

¹Voyager Therapeutics, Lexington, United States, ²Voyager Therapeutics Contractor, Lexington, United States

00133 - The PRImus-AD study: design of the phase 2 study treating patients with MCI or mild dementia due to Alzheimer's disease (AD) with the orally available PRI-002

Presenter: Dieter Willbold

Dieter WILLBOLD^{1,2}, Dagmar JÜRGENS ¹, Tischler GERHARD ³, Brener ALEXANDER ³, Bartsch TINA ³, Kauselmann GUNTHER ¹, Adermann KNUT ¹, Zeiger KATHRIN ³, Kindner KATJA ³, Gabelich JULIE-ANNE ³, Peters OLIVER ⁴

¹Priavoid GmbH, Düsseldorf, Germany, ²Heinrich Heine University Düsseldorf, Institute of Physical Biology, Düsseldorf, Germany, ³PRInnovation GmbH, Düsseldorf, Germany, ⁴Charite, Berlin, Germany

00129 - A Phase 3 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Evaluate Safety and Efficacy of NA-831 as Monotherapy and in Combination with Donanemab in Subjects with Early Alzheimer's Disease

Presenter: Lloyd Tran

Lloyd TRAN, Fern VU, Zung TRAN

¹Biomed Industries, Inc., San Jose, United States

00081 - VHB937, a TREM2 stabilizing and activating fully human monoclonal antibody: A Phase 2 study design in Alzheimer's disease and rationale

Presenter: Ana Graf

Ana GRAF ¹, Dominik FEUERBACH ¹, Derya SHIMSHEK ¹, Judit SOVAGO ¹, Gisela PERAUS ¹, Aileen ZHU ², Catherine AGOROPOULOU ¹, Alexandra BOBIRCA ¹, Carmen SERBAN ¹

Novartis Pharma AG, Basel, Switzerland, ²Novartis, Shanghai, China

00096 - Baseline demographics and patient characteristics in a Phase 3 registration trial for AR1001 for the treatment of early Alzheimer's disease: POLARIS-AD

Presenter: Sharon J Sha

Sharon J. SHA ¹, Fernando MELGAR-SOMOZA ², Marzena ZBOCH ³, Do Hoon KIM ⁴, Yi TANG ⁵, Jennifer LYNCH ⁶, Howard CHERTKOW ⁷, Sangyun KIM ⁸, James A. ROCK ⁹, Fred KIM ⁹, Jai Jun CHOUNG ⁹

¹Stanford University, Palo Alto, United States, ²Melgar-Caro MedCenter and Community Research, Miami, United States, ³Wroclawskie Centrum Alzheimerowski - Wdroclow (Poland), Wdroclow, Poland, ⁴Department of Psychiatry, Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea, ⁵Xuanwu Hospital Capital Medical University, Beijing, China, ⁶Department of Psychiatry, Chuncheon Sacred Heart Hospital, Chuncheon, United Kingdom, ⁷Baycrest Centre for Geriatric Care, Motherwell, Canada, ⁸Seoul National University College of Medicine & Seoul National University, Bundang, Republic of Korea, ⁹AriBio Co., Ltd, San Diego, United States

00054 - Successful Strategies for Recruitment and Retention as a Foundation for ADRD-focused Clinical Trials in a Rural Cohort

Presenter: Lisa Wiese

Lisa WIESE ¹, Christine WILLIAMS ¹, Diane J. COOK ², Juyoung PARK ³, Jan HOLT ¹, Diana MITSOVA ¹, Sheryl MAGZAMEN ⁴, Lilah BESSER ⁵, Madeline TOURELLE ⁵

¹Florida Atlantic University, Boca Raton, United States, ²Washington State University, Pullman, United States, ³Washington State University, Phoenix, United States, ⁴Colorado State University, Fort Collins, United States, ⁵University of Miami, Miami, United States

00291 - Effect of consenting clinician degree on screen fail rate in Alzheimer's Disease clinical trials

Presenter: Ralph Lee

Yu-Jay HUOH, Razyya ABDULMUMIN, James LUAYON, Dana NGUYEN, Tara PARNITVITHIKUL, Elizabeth SOSA, Edward ZAMRINI, Ralph LEE

¹Irvine Clinical Research, Irvine, United States

00287 - Click or Clinic? Comparing Referral-to-Pre-Screen Attendance Rates Between Digital divertisements and HCP Referrals in Alzheimer's Clinical Trials

Presenter: Thibaud Belleface

Thibaud BELLEFACE, Jeffrey APTER

¹Global Medical Institutes, Princeton, United States

00280 - Minimal clinically important differences are often misapplied and misinterpreted and should be used with caution

Presenter: Patrick O'keefe

Patrick O'KEEFE, Mitchell WASSOM, Kent HENDRIX, Craig MALLINCKRODT, Suzanne HENDRIX, Samuel DICKSON

¹Pentara, Millcreek, United States

00095 - Rethinking Interim Analyses: When and Why to Avoid Them

Presenter: Samuel Johnson

Samuel JOHNSON, Katelyn MILLER, Kent HENDRIX, Craig MALLINCKRODT, Suzanne HENDRIX, Samuel DICKSON

¹Pentara Corporation, Millcreek, United States

00124 - Improving Study Power Through Continuous Modeling of a Global Treatment Effect Versus Composite Responder Analysis

Presenter: Abe Durrant

Abe DURRANT ¹, Andrew MILLANE ¹, Craig MALLINCKRODT ¹, Kent HENDRIX ¹, Suzanne HENDRIX ¹, Samuel DICKSON ¹

¹Author, Salt Lake City, United States

00143 - Feasibility of Participants with Symptomatic Alzheimer's Disease to Self-Administer Remternetug Subcutaneously: Results from the TRAILRUNNER-ALZ 1 Phase 3 Trial

Presenter: Matthew Hufford

Matthew HUFFORD, Kevin BIGLAN, Chad STROUD, Anna Eames SEFFERNICK, Meilin JIANG, Mausumi LIDOGASTER, Matan DABORA

¹Eli Lilly and Company, Indianapolis, United States

00234 - Breaking down the influences of placebo progression and percent slowing in the context of time saved in Alzheimer's Disease clinical trials for populations in different disease stages

Presenter: Caleb Dayley

Caleb DAYLEY, Suzanne HENDRIX, Samuel DICKSON, Kent HENDRIX, Jason COOK

¹Pentara Corporation, Millcreek, United States

00215 - The effect of corticosteroid pre-treatment with modified titration of donanemab on amyloid reduction and safety: TRAILBLAZER-ALZ 6 addendum design

Presenter: Hong Wang

Emel Serap NERY ¹, Hong WANG ¹, Paul ARDAYFIO ¹, Rashna KHANNA ¹, Diana SVALDI ¹, Sergey SHCHERBININ ¹, Wen XU ¹, Paula HAUCK ¹, Jin-Tai YU ², Jiong SHI ³, Dawn BROOKS ¹, Emily COLLINS ¹, Mark MINTUN ¹, John SIMS ¹

¹Eli Lilly and Company, Indianapolis, United States, ²Huashan Hospital, Shanghai, China, ³The First Affiliated Hospital of University of Science and Technology of China, Hefei, China

00206 - Study Insight Analytics (SIA) Algorithms Validation for SMART Independent Review of the ADAS-Cog Scale

Presenter: Selam Negash

Selam NEGASH, Matt WELCH, B ECHEVARRIA, Chris RANDOLPH

¹Clario, Philadelphia, United States

00170 - REACHED – a pilot study exploring electronic health records and digital assessments to identify potential participants from understudied populations for clinical studies in Alzheimer’s disease

Presenter: Ruth Croney

Frank BOESS ¹, Nicola MAIORANO ¹, Janice SMITH ², Alexandria WISE-BROWN ³, Kelly COULTES ⁴, Giuseppe FILOSA ¹, Frank PERILLI ⁵, Erin BECK ⁵, Ira GOODMAN ⁵, Ruth CRONEY ²

¹F. Hoffmann-La Roche, AG, Basel, Switzerland, ²Roche Products Ltd, Welwyn Garden City, United Kingdom, ³Genentech, Inc., South San Francisco, United States, ⁴F. Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵SiteRx, New York, United States

00078 - Web-Based Prescreening Survey for Alzheimer’s Disease Clinical Trials: Enhancing Efficiency and Diversity

Presenter: Elisabeth Burnett

Elisabeth BURNETT, Anna SLADKY, Jenny ECHEVARRIA MEDINA, Ijeoma MBA, Patricia LOWE, Karen COLOMBO, Terrence LAFRANCE, Mariah ALEXIS, Juris JANAUS, Lauren MARCONI, Joette GIOVINCO, Ram BISHNOI, Amanda SMITH, Wendy BELDEN

¹USF Health Byrd Alzheimer’s Institute, Tampa, United States

00018 - Trends on patients’ recruitment and retention in Alzheimer’s disease modification trials.

Presenter: Karla Kanis

Andreas LYSANDROPOULOS ¹, Jessica GARINGER ², Karla KANIS²

¹Parexel, Wavre, Belgium, ²Parexel, Newton, United States

02 ● CLINICAL TRIALS: RESULTS

00289 - A Phase 1 Clinical Trial of BDNF Gene Therapy for AD and MCI: Update

Presenter: Mark Tuszyński

Douglas SCHARRE ¹, Gabriel LEGER ², Russell LONER ³, Krzysztof BANKIEWICZ ³, Mark TUSZYŃSKI ²

¹Ohio State University Medical Center, Columbus, United States, ²UC San Diego, La Jolla, United States, ³Ohio State University, Columbus, United States

00189 - Randomised controlled trial of extended-release guanfacine in Alzheimer’s disease dementia (NorAD)

Presenter: Paresh Malhotra

Paresh MALHOTRA ¹, Hilary WATT ¹, Karen HOANG ², Mara GOLEMME ¹, Johanna BRANDT ³, Chara TRIANTAFYLLOU ¹, Richard PERRY ¹, Praveen SINGH ⁴, Craig RITCHIE ⁵, Danielle WILSON ¹, James PICKETT ⁶, Chris FOX ⁷, Rachel BURTON ³, James CARPENTER ³, Robert HOWARD ³

¹Imperial College London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom, ³University College London, London, United Kingdom, ⁴Central and North West London NHS Foundation Trust, London, United Kingdom, ⁵Brain Sciences Scotland, London, United Kingdom, ⁶Owkin, London, United Kingdom, ⁷University of Exeter, London, United Kingdom

00191 - Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer’s Disease

Presenter: Jonas Svensson

Helen ANNERNVIK-WALLGREN ¹, Miia KIVIPELTO ², Pontus PLAVEN-SIGRAY ², Jonas SVENSSON ²

¹Karolinska University Hospital, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden

00219 - Results of a «First-in-Human» Open Label, Phase 1 Clinical Study of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous, Wnt Activated, Adipose-Derived Stem Cells in 6 Participants

with Mild to Moderate Alzheimer's Disease (AD)

Presenter: Christopher Duma

Christopher DUMA ¹, Hans KEIRSTEAD ¹, Gabriel NISTOR ¹, Robert LYNN ¹, Gus ALVA ², Karlyssa CHUNG ¹, Ashley HARRIS ¹, Sawyer FARMER ¹, Jessica BUXTON ¹, Zoe HARENG ¹

¹Regeneration Biomedical, Inc., Newport Beach, United States, ²Hoag Memorial Hospital Presbyterian, Newport Beach, United States

00135 - Results of a Phase II Randomized, Double-Blind, Placebo-Controlled Trial of S-Adenosyl Methionine in Participants with Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease

Presenter: Sarah Holper

Sarah HOLPER ^{1,2,3}, Kevin J. BARNHAM ³, Leonid CHURILOV ¹, Paul YATES ^{4,5}, Amy BRODTMANN ⁶, Sally JOHNS ⁷, Colin L. MASTERS ^{3,8}, Rosie WATSON ^{1,2}, Nawaf YASSI ^{1,2,3}

¹Department of Medicine, Melbourne Brain Centre @ The Royal Melbourne Hospital, University of Melbourne, Parkville, Vic, Australia,

²Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Vic, Australia, ³The Florey Institute of Neuroscience and Mental Health, Parkville, Vic, Australia, ⁴Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Vic, Australia, ⁵Medical and Cognitive Research Unit, Department of Geriatric Medicine, Austin Health, Heidelberg, Vic, Australia, ⁶Department of Neurology, Eastern Health, Monash University, Box Hill, Vic, Australia, ⁷Department of Geriatric Medicine, Modbury Hospital, Northern Adelaide Local Health Network, South Australia, Australia, ⁸University of Melbourne, Parkville, Vic, Australia

00162 - ABvac40 Vaccine Is Associated with Reduced Cortical Perfusion Decline in Early-Stage Alzheimer's Disease: Results from the AB1601 Phase 2 Study

Presenter: María Pascual-Lucas

María PASCUAL-LUCAS ¹, Ana María LACOSTA ¹, María MONTAÑÉS ¹, Jesús CANUDAS ¹, Jorge LOSCOS ¹, Jose TERCICIO ^{1,2}, Elena PRIETO ³, Kathie HIRSCHMUELLER ³, Javier ARBIZU ³

¹Araclon Biotech-Grifols, Zaragoza, Spain, ²Grifols, Barcelona, Spain, ³Clínica Universidad de Navarra, Pamplona, Spain

00059 - The ORCHID Study: Optimizing Rural Community Health through Interdisciplinary Detection and Care

Presenter: Lisa Wiese

Lisa WIESE ¹, Candy WILSON ¹, Beth KING ¹, Bianca TOLEA ², Magdalena TOLEA ²

¹Florida Atlantic University, Boca Raton, United States, ²University of Miami, Miami, United States

00107 - VNA-318, a first-in-class small molecule with a unique dual mode of action, exhibits properties in the first-in-human trial ideal for becoming a novel combination partner in the treatment of patients with Alzheimer's Disease

Presenter: Klaus Dugi

Klaus DUGI ¹, Marina KLEIN ², Silke KERN ¹, Tanes IMAMURA DE LIMA ¹, Leila MIRMOHAMADSADEGHI ¹, Penelope ANDREUX ¹

¹Vandria Ltd, Epalinges, Switzerland, ²Biotrial, Rennes, France

00021 - Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blar-camesine

Presenter: Marwan Sabbagh

Marwan SABBAGH ¹, Timo GRIMMER ², Juan Carlos LOPEZ-TALAVERA ³, William CHEZEM ³, Kun JIN ³, Christopher MISSLING ³

¹Barrow Neurological Institute, Phoenix, United States, ²Technical University of Munich, Munich, Germany, ³Anavex, New York, United States

00052 - Semaglutide Concentration in Cerebrospinal Fluid from Patients with Early Alzheimer's Disease After 12 Weeks of Subcutaneous Treatment

Presenter: Peter Johannsen

Peter JOHANNSEN ¹, Marie Aare BENTSEN ¹, Dylan Mathew BELMONT-RAUSCH ¹, Lisbeth CARSTENSEN ¹, Rose JEPPESEN ¹, Gabriel MARTINO ¹, Martí JIMÉNEZ-MAUSBACH ¹, Anne BÖRJESSON-HANSON (2, 3), Lotte Bjerre KNUDSEN ¹

¹Novo Nordisk, Copenhagen, Denmark, ²Department of Aging, Karolinska University Hospital, Stockholm, Sweden, ³Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden

00176 - Analytical and clinical validation of the APOE genotyping PCR test in patients from the Phase III Clarity AD trial.

Presenter: Kozue Matsuda

Kozue MATSUDA

¹Sysmex Corporation, Kobe, Japan

00016 - Brexpiprazole Treatment for Agitation Associated with Dementia due to Alzheimer's Disease: Post

Hoc Subgroup Analysis Based on Care Setting (Inpatient/Outpatient) in Brexpiprazole for Alzheimer's Disease Patients with Agitated Symptoms (BRIDGE) Study

Presenter: Shimizu Koichi

Shimizu KOICHI ¹, Seiyama YUTA ², Shibasaki YOSHIYUKI ¹, Toda RIKIYA ¹, Nakamichi NORIHIRO ¹, Adachi JUN ³, Hirota NAOKI ⁴, Nakai MASAMI ⁴, Takahashi KANEYOSHI ¹, Nakamura YU ⁵

¹Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, ²Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Osaka, Japan, ³Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, ⁴Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd, Osaka, Japan, ⁵Faculty of Medicine/Graduate School of Medicine, Kagawa University, Kagawa, Japan

00008 - Assessment of Orthostatic tolerance and Efficacy of Fimasartan in elderly Alzheimer's disease patients with Hypertension: A 16-Week Observational study

Presenter: Mee Y Park

Mee Y. PARK ¹, Hyeun J. HAN ², Jean S. AN ³

¹Yeungnam Medical University Center, Daegu, Republic of Korea, ²Ilsan Brain Neurology Clinic, Ilsan, Republic of Korea, ³University of Illinois Chicago, Chicago, United States

03 ● CLINICAL TRIALS: IMAGING

00267 - Comparing Tau PET Tracers for Biological Staging in Early Alzheimer's: Implications for Trial Enrichment

Presenter: Marina Scop Medeiros

Marina SCOP MEDEIROS ^{1,2}, Lucas SCHILLING ², Emma RUPPERT ¹, Pamela FERREIRA ¹, Joseph MASDEU ³, David SOLEIMANI-MEIGOONI ⁴, Juan FORTEA ⁵, Pedro ROSA-NETO ⁶, Val LOWE ⁷, Hwamee OH ⁸, Belen PASCUAL ³, Brian GORDON ⁹, Dana TUDORASCU ¹, Suzanne BAKER ¹⁰, Tharick PASCOAL ¹

¹University of Pittsburgh, Pittsburgh, United States, ²Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil, ³Houston Methodist, Houston, United States, ⁴University of California San Francisco, San Francisco, United States, ⁵Sant Pau, Barcelona, Spain, ⁶McGill University, Montreal, Canada, ⁷Mayo Clinic, Rochester, United States, ⁸Brown University, Providence, United States, ⁹Washington University, St Louis, United States, ¹⁰Lawrence Berkeley, Berkeley, United States

00172 - Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET

Presenter: Robin Wolz

Colm MCGINNITY, Anthony S. GABAY, Katherine R. GRAY, R MANBER, R JOULES, Robin WOLZ

¹IXICO, London, United Kingdom

00232 - Extending the CenTauR Standardization Framework to the Voxel Level: Preliminary Validation Using [¹⁸F]flortaucipir and [¹⁸F]MK-6240

Presenter: Alexis Moscoso

Alexis MOSCOSO ¹, Antoine LEUZY ², Victor L. VILLEMAGNE ³, Alex DEL BENE ⁴, Brian LOPRESTI ⁴, Alexandra GOGOLA ⁴, Gregory KLEIN ⁵, Hartmuth C KOLB ⁶, Nadine TATTON ⁷, Yashmin KARTEN ⁷, Matteo TONIETTO ⁵, Emily OLAFSON ⁸, Ruben SMITH ⁹, Oskar HANSSON ⁹, Vincent DORÉ ¹⁰

¹Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path Institute, Tucson, United States; Nuclear medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, Spain ²Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path Institute, Tucson, United States; Enigma Biomedical Group, Knoxville, United States ³Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United States; Department of Molecular Imaging & Therapy, Austin Health, Victoria, Australia ⁴Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, United States ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland ⁶Enigma Biomedical Group, Knoxville, United States ⁷Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path Institute, Tucson, United States ⁸Clinical Imaging Group, Genentech, Inc., South San Francisco, United States ⁹Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Sweden ¹⁰Department of Molecular Imaging & Therapy, Austin Health, Victoria, Australia; Health and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO, Victoria, Australia

00222 - Evaluating the Effects of Non-Linear SUVR Transformations for Harmonization on Statistical Power in Longitudinal Tau-PET Studies

Presenter: Alexs Moscoso

Alexs MOSCOSO ^{1,2}, Antoine LEUZY ^{1,3}, Hartmuth KOLB ³, Victor VILLEMAGNE ^{4,5}, Gregory KLEIN ⁶, Brian LOPRESTI ⁷, Alexandra GOGOLA ⁷, Diane STEPHENSON ¹, Nadine TATTON ¹, Yashmin KARTEN ¹, Fang XIE ⁸, Christopher C ROWE ^{9,10}, Vincent DORÉ ^{9,11}

¹Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path Institute, Tucson, United States, ²Nuclear Medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n., Santiago De Compostela., Spain, ³Enigma Biomedical Group, Knoxville, United States, ⁴Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United States, ⁵Department of Molecular Imaging & Therapy, Austin Health, Victoria, Australia, ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁷Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, United States, ⁸Department of Nuclear Medicine & PET Center, Huashan Hospital, University, Shanghai, China, ⁹Florey Department of Neuroscience, University of Melbourne, Victoria, Australia, ¹⁰The Australian Dementia Network (ADNeT), The University of Melbourne, Victoria, Australia, ¹¹Health and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO, Victoria, Australia

00212 - Developing a harmonized visual reading method towards the clinical use of tau-PET tracers

Presenter: Emma Ruppert

Emma RUPPERT ¹, Marina SCOP MEDEIROS ¹, Marie VERMEIREN ², Guilherme POVALA ¹, Firoza LUSSIER ¹, David SOLEIMANI-MEIGOONI ³, Juan FORTEA ⁴, Val LOWE ⁵, Hwamee OH ⁶, Belen PASCUAL ⁷, Brian GORDON ⁸, Pedro ROSA-NETO ⁹, Suzanne BAKER ¹⁰, Tharick PASCOAL ¹

¹University of Pittsburgh, Pittsburgh, United States, ²Amsterdam UMC, Amsterdam, Netherlands, ³University of San Francisco, San Francisco, United States, ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Mayo Clinic, Rochester, United States, ⁶Brown University, Providence, United States, ⁷Houston Methodist Research Institute University, Houston, United States, ⁸Washington University in St. Louis Methodist Research Institute University, St. Louis, United States, ⁹McGill University, Montréal, Canada, ¹⁰Lawrence Berkeley National Laboratory, Berkeley, United States

00196 - Functional Network Segregation as a Neural Correlate of Cognitive Reserve in Alzheimer's Disease Spectrum

Presenter: Na Young Yeo

Na Young YEO ¹, Christian G. HABECK ², Yaakov STERN ², Jae-Won JANG ³, Yeshin KIM ³

¹Kangwon National University, Chuncheon, Republic of Korea, ²Columbia University, New York, United States, ³Kangwon National University Hospital, Chuncheon, Republic of Korea

00180 - Lower Antemortem [18F]flortaucipir PET retention in Males and Older Individuals is Explained by Lower Postmortem Tau Tangle Density

Presenter: Emma Coomans

Emma COOMANS ^{1,2}, Ruben SMITH ^{3,4}, Sebastian PALMQVIST ^{3,4}, Michael PONTECORVO ⁵, Sergey SHCHERBININ ⁵, Vikas KOTARI ⁵, Thomas BEACH ⁶, Geidy SERRANO ⁶, Erik STOMRUD ^{3,4}, Niklas MATTSSON-CARLGREN ^{3,7}, Wiesje VAN DER FLIER ^{1,2}, Yolande PIJNENBURG ^{1,2}, Elsmarieke VAN DE GIESSEN ^{8,9}, Oskar HANSSON ³, Rik OSSENKOPPELE ^{1,3}

¹Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands ²Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands ³Clinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden ⁴Memory Clinic, Skåne University Hospital, Malmö, Sweden ⁵Eli Lilly and Company, Indianapolis, United States, Indianapolis, United States, ⁶Eli Lilly and Company, Indianapolis, United States ⁷Department of Neurology, Skåne University Hospital, Lund University, Lund, Sweden ⁸Department of Radiology & Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands ⁹Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands

00104 - Towards correcting for pseudo atrophy in monoclonal antibody clinical trials on Alzheimer's disease: a model of amyloid-removal related atrophy predicts treatment benefit

Presenter: Neil Oxtoby

Neil OXTOBY ¹, Bojidar RANGELOV ¹, Michael DONOHUE ²

¹UCL Hawkes Institute and Department of Computer Science, University College London, London, United Kingdom, ²Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, United States

00155 - Recommendations for DTI harmonization in multicenter clinical trials.

Presenter: Madhura Ingathalikar

Madhura INGATHALIKAR ¹, Stefan RADONJIC ¹, Luc BRACAUD ², Chris CONKLIN ¹, Meredith BURKE ¹, David SCOTT ¹, Adni ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE ³

¹Clario, Philadelphia, United States, ²Clario, Lyon, France, ³ADNI, United States

00154 - Associations of amyloid-beta with entorhinal cortical thickness and episodic memory among a diverse oldest-old cohort: The Life After 90 Study

Presenter: Batool Rizvi

Batool RIZVI ¹, Christina YOUNG ¹, Molly LAPOINT ², Adam BRICKMAN ³, Pauline MAILLARD ¹, Charles DECARLI ¹, Paola GILSANZ ², Maria CORRADA ⁴, Rachel WHITMER ¹

¹UC Davis, Davis, United States, ²Kaiser Permanente Northern California Division of Research, Pleasanton, United States, ³Columbia University, New York, United States, ⁴UC Irvine, Irvine, United States

00069 - Impact of 40Hz tACS on regional glymphatic flow in patients with mild Alzheimer's disease

Presenter: Lu Yuanyuan

Lu YUANYUAN, Xing YI, Tang YI

¹Xuanwu Hospital, Capital Medical University, Beijing, China

00275 - Allopregnanolone Increases Hippocampal Volume in Early Alzheimer's Disease: Importance of Segmentation Method and Baseline Atrophy

Presenter: Roberta D. Brinton

Adam C., RAIKES ¹, Dawn MATTHEWS ², Gerson HERNANDEZ ¹, Ana S. LUKIC ², Randolph D. ANDREWS ², Claudia LOPEZ ¹, Lon SCHNEIDER ³, Roberta D. BRINTON ¹

¹Center for Innovation in Brain Science, University of Arizona, Tucson, United States, ²ADM Diagnostics, Chicago, United States, ³Keck School of Medicine, University of Southern California, Los Angeles, United States

00148 - Longitudinal Impact of Sarcopenia on Amyloid Deposition, Brain Atrophy, and Cognitive Decline: A Multi-modal Linear Mixed Model Analysis

Presenter: Sunghwan Kim

Sunghwan KIM ¹, Sheng-Min WANG ¹, Dong Woo KANG ², Yoo Hyun UM ³, Su-Hyeong KIM ³, Yoon HAN MIN ¹, Hyun Kook LIM ¹

¹The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul, Republic of Korea, ²The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Republic of Korea, ³The Catholic University of Korea, St. Vincent's Hospital, Suwon, Republic of Korea

00230 - Exploring Individual Variation in Tau PET and CDR-SB: A Meta-Analysis of Placebo Arm Data

Presenter: Yashmin Karten

Yashmin KARTEN ¹, Dries DE WITTE ², Gregory KLEIN ³, Antoine LEUZY ^{4,1}, Alexis MOSCOSO RIAL ^{5,1}, Philip INSEL ⁶, Ariel Alonso ABAD ^{2,7}, Geert MOLENBERGHS ^{2,7}, Nadine TATTON ¹, Cpad ON BEHALF OF THE CRITICAL PATH FOR ALZHEIMER'S DISEASE CONSORTIUM ¹

¹Critical Path Institute, Tucson, United States, ²L-BioStat, KU Leuven, Leuven, Belgium, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Enigma Biomedical Group, Knoxville, United States, ⁵Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n., Santiago De Compostela, Spain, ⁶University of California, San Francisco, San Francisco, United States, ⁷I-BioStat, Hasselt, Belgium

00140 - Advancing Clinical Research with PET Imaging: Emerging Radiotracers and Evolving Roles in Alzheimer's Dementia Diagnosis

Presenter: Abby Fuller

Ioan Laurentiu GUTIU ¹, Abby FULLER ², Tetyana KORCHAK ²

¹Fortrea GmbH, Munich, Germany, ²Fortrea, Durham, United States

04 ● CLINICAL TRIALS: BIOMARKERS INCLUDING PLASMA

00263 - Validation of an Alzheimer's Disease conformation-specific p53 antibody in patient samples

Presenter: Shmuel Agus

Shmuel AGUS ¹, David LYNCH ², Simona PICCIRELA ³, Madisson SAMPLES ², Michael RASCHE ⁴, Rakez KAYED ²

¹Diadem Inc, Roslindale, United States, ²UTMB, Galveston, United States, ³Diadem SpA, Milan, Italy, ⁴Diadem SpA, Munich, Germany

00261 - Concordance of ApoE proteotype vs genotype assays: a low friction method for obtaining E4 carrier status

Presenter: Gallen Triana-Baltzer

Gallen TRIANA-BALTZER ¹, Thierry VERBINNEN ², Silke MILLER ¹, Ziad SAAD ¹, Janice WONG ³, David HENLEY ³, Yanina FLOSSBACH ², Gahan PADINA ³, Stanley BELKOWSKI ³

¹Johnson & Johnson, San Diego, United States, ²Johnson & Johnson, Beerse, Belgium, ³Johnson & Johnson, Springhouse, United States

00245 - Targeted Plasma Proteomic Biomarker Profiling in the FINGER Multimodal Lifestyle Intervention Trial

Presenter: Anna Matton

Anna MATTON ^{1,2,3}, Alina SOLOMON ^{3,4}, Andrea LESSA BENEDET ⁵, Jenni LEHTISALO ⁶, Esko LEVÄLAHTI ⁶, Anna ROSENBERG ⁷, Makrina DANILIDOU ^{8,2}, Francesca MANGIALASCHE ^{8,2,9}, Henrik ZETTERBERG ⁵, Tiia NGANDU ⁶, Miia KIVIPELTO ⁸

¹Department of Neurobiology, Care Sciences and Society, Karolinska Institutet Stockholm, Sweden, ²FINGERs Brain Health Institute, Stockholm, Sweden, ³The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, United Kingdom, ⁴Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland, ⁵Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden, ⁶Department of Public Health, Lifestyles and Living Environments, Finnish Institute for Health and Welfare, Helsinki, Finland, ⁷Department, Helsinki, Finland, ⁸Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden, ⁹Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden

00231 - Does Amyloid Plaque Reduction Mediate the Clinical Effect of Amyloid-targeting Antibodies?

Presenter: Lon Schneider

Lon SCHNEIDER ¹, James LUO ¹, Richard KENNEDY ²

¹Keck School of Medicine of USC, Los Angeles, United States, ²University of Alabama Birmingham, Birmingham, United States

00226 - Age-related changes in plasma p-tau217 and reference levels in cognitively unimpaired Aβ-negative individuals

Presenter: Anna Mammel

Anna MAMMEL ¹, Ali MOUSAVI ^{2,3}, Kelsey HALLETT ¹, Mary ENCARNACION ², Donald BIEHL ¹, Pradip GILL ¹, Fernando GONZALEZ ^{1,4}, Hans FRYKMAN ^{1,2,3}

¹Neurocode, Bellingham, United States, ²BC Neuroimmunology, Vancouver, Canada, ³University of British Columbia, Vancouver, Canada, ⁴University of Gothenburg, Gothenburg, Sweden

00213 - A Comparative Analysis of Creatinine- and Cystatin C-based eGFR equations for the Assessment of Chronic Kidney Disease Influence on Plasma p-tau217 Concentrations

Presenter: Joshua Bornhorst

Joshua BORNHORST ¹, Stephen WEIGAND ², Daniel FIGDORE ¹, Michael GRISWOLD ³, Carly LUNDGREEN ², Heather WISTE ², Prashanthi VEMURI ⁴, Jonathan GRAFF-RADFORD ⁵, David KNOPMAN ⁵, Petrice COGSWELL ⁴, Clifford JACK JR. ⁴, Ronald PETERSEN ⁵, Alicia ALGECIRAS-SCHIMNICH ¹

¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, United States, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, United States, ³Center of Biostatistics and Bioinformatics University of Mississippi Medical Center, Jackson, United States, ⁴Department of Radiology, Mayo Clinic, Rochester, United States, ⁵Department of Neurology, Mayo Clinic, Rochester, United States

00200 - Research on Biomarkers of Early Alzheimer's Disease in China in the past decade a scoping review

Presenter: Guoping Peng

Guoping PENG ¹, Yan YANG ², Ying WANG ², Sagar Anil CHANDEKAR ³, Jintai YU ⁴

¹Department of Neurology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, ²Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China, ³Novo Nordisk A/S, Søborg, Denmark, ⁴Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

00160 - Clinical Trial Patient Cohort Enrichment Using Cost-Effective Blood-Based Biomarker Screening

Presenter: Noah Elder

Robert LIN ¹, Jason WAN ¹, Noah ELDER ¹, Hien NGUYEN ¹, Paul HUNG ¹

¹Taudia, San Carlos, United States

00083 - P-tau217 testing impact on patient management in a racially/ethnically diverse population: six-month follow up in a randomized clinical utility study.

Presenter: Rose C. Beck

Samantha C. BURNHAM ¹, Haoyan HU ¹, Yifeng TANG ¹, Anthony SIRECI ¹, Michael J. PONTECORVO ¹, Paul E. SCHULZ ², Curtis P. SCHREIBER ³, Rose C. BECK ¹

¹Eli Lilly & Company, Indianapolis, United States, ²Neurocognitive Disorders Center, McGovern Medical School of UTHealth, Houston, Texas, United States, ³Missouri Memory Center, Citizen's Memorial Hospital, Bolivar, Missouri, United States

00056 - Novel biomarkers drive a distinct pattern of clinical characterization of two cohorts: a Chinese Aging and Neurodegenerative Disorder Initiative (CANDI) and a Hefei Aging Study Urban Community (HAS)

Presenter: Yong Shen

Yong SHEN

¹University of Science and Technology of China, Hefei, China

00011 - Migrating the use of plasma p-tau217 from research setting to clinical practice: a real-world study in Subjective Cognitive Decline and Mild Cognitive Impairment

Presenter: Giulia Giacomucci

Giulia GIACOMUCCI ¹, Chiara CRUCITTI ¹, Assunta INGANNATO ¹, Silvia BAGNOLI ¹, Elisa MARCANTELLI ¹, Sonia PADIGLIONI ², Valentina MOSCHINI ², Carmen MORINELLI ², Salvatore MAZZEO ³, Sandro SORBI ⁴, Benedetta NACMIAS ¹, Valentina BESSI ¹

¹Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy, ²Research and Innovation Centre for Dementia-CRIDEM, AOU Careggi, Florence, Italy, ³Vita-Salute San Raffaele University, Milan, Italy, ⁴IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy

00284 - Regional Amyloid Positivity Predicts Alzheimer's Disease Progression Despite Low Centiloid Values in Mild Cognitive Impairment

Presenter: Oh Minyoung

Oh MINYOUNG ¹, Ryu JEONGRYUL ¹, Lim JAE-SUNG ², Kim JAE SEUNG ¹, Lee JAE-HONG ²

¹Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, ²Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

00272 - Head-to-head comparison of 4 capillary blood sampling devices for measuring p217 tau

Presenter: Setareh Moughadam

Setareh MOUGHADAM ¹, Hanna HUBER ², Laia MONTOLIU-GAYA ², Nicholas ASHTON (2, 3), Henrik ZETTERBERG ², Annemie CHIAU ⁴, Katrin HAEVERANS ⁵, Gallen TRIANA BALTZER ¹

¹Johnson and Johnson, San Diego, United States, ²University of Gothenburg, Gothenburg, Sweden, ³Banner Alzheimer's Institute, Phoenix, United States, ⁴ICON, Beerse, Belgium, ⁵Johnson and Johnson, Beerse, Belgium

00122 - Leveraging recent advances in biomarkers to optimize early phase drug development in Alzheimer's Disease

Presenter: Garrett Duncan

Garrett DUNCAN

¹Pentara Corporatoin, Salt Lake City, United States

00253 - Identifying Neuropsychological and Sociodemographic Predictors of a Blood-Based Biomarker of Alzheimer's Disease

Presenter: Isaiah Gamble

Isaiah GAMBLE, Stephanie RUTRICK, Sarah STARLING, Hailie HALE, Jake PETITT, Sean WOMACK

¹Adams Clinical, Watertown, United States

00075 - MK-1167, a positive allosteric modulator of $\alpha 7$ nicotinic cholinergic receptors: proof-of-biology, dose selection, and clinical trial design

Presenter: Sarah Janicki Hsieh

Sarah Janicki HSIEH ¹, Corin MILLER ¹, Graeme MASON ², Douglas ROTHMAN ², Gerard SANACORA ², Evita C. WIEGERS ³, Dennis W. J. KLOMP ³, Narjes AHMADIAN ³, Sarah JACOBS ³, An BAUTMANS ⁴, Kristien VAN DYCK ⁴, Yi MO ¹, Michael F. EGAN ¹, S Aubrey STOCH ¹, Mk-1167-003 Clinical Study Team ^{1,3}

¹Merck & Co., Inc., Rahway, United States, ²Yale School of Medicine, New Haven, United States, ³University Medical Center, Utrecht, Netherlands, ⁴MSD Europe Belgium, Brussels, Belgium

00177 - Optimizing Plasma p-Tau217 Cutoffs for Amyloid Pathology According to Kidney Function, Body Weight, and Anemia

Presenter: Jihwan Yun

Jihwan YUN ¹, Daeun SHIN ², Eun Hye LEE ², Jun Pyo KIM ², Hongki HAM ², Yuna GU ², Min Young CHUN ³, Sung Hoon KANG ⁴, Hee Jin KIM ², Duk L. NA ⁵, Henrik ZETTERBERG ⁶, Kaj BLENNOW ⁶, Fernando GONZALEZ-ORTIZ ⁶, Sang Won SEO ², Hyemin JANG ⁷

¹Department of Neurology, Kyung Hee University College of Medicine, Kyung Hee University Hospital,, Seoul, Republic of Korea,

²Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea,

³Department of Neurology, Yonsei Severance Hospital, Yonsei University Health System, Yonsei, Republic of Korea, ⁴Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea, ⁵Happymid Clinic, Neurology, Seoul, Republic of Korea, ⁶Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden, ⁷Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

00192 - Predicting Alzheimer's Disease Progression Using Neuroimaging and Genetics Markers

Presenter: Seok Woo Moon

Seok Woo MOON ¹, Bumjun KIM ¹, Ivo DINOVI ²

¹Konkuk University Chungju Hospital, Chungju, Republic of Korea, ²UMICH, Ann Arbor, United States

00169 - Semaglutide impacts proteomic signatures related to dementia risk in the SELECT cardiovascular outcomes trial

Presenter: Martí Jiménez-Mausbach

Martí JIMÉNEZ-MAUSBACH¹, Jan Christian REFSGAARD ¹, Gabriel MARTINO¹, Teresa Leon COLOMBO¹, Betty TIJMS ², Clare PATERSON³

¹Novo Nordisk A/S, Søborg, Denmark, ²Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands, ³Clinical Research and Development, Standard BioTools, Boulder, Colorado, United States

00161 - Robustness of Plasma Aβ42/Aβ40 as a Predictive Biomarker for Brain Amyloid Deposition: Independence from Renal Function and Body Mass Index in a Real-World Tertiary Care Cohort with Mild Cognitive Impairment.

Presenter: José Antonio Allué

José Antonio ALLUÉ ¹, Leticia SARASA ¹, Noelia FANDOS ¹, Jorge LOSCOS ¹, Judith ROMERO ¹, Adrián SÁNCHEZ ¹, Jose TERCICIO ^{1,2}, Gerard PIÑOL-RIPOLL ^{3,4}, María PASCUAL-LUCAS ¹

¹Araclon Biotech-Grifols, Zaragoza, Spain, ²Grifols S.A., Barcelona, Spain, ³Hospital Universitari Santa Maria, Lleida, Spain, ⁴Hospital Clínic, Barcelona, Spain

00151 - Modeling Age-Related Amyloid-β Trajectories in Cognitively Unimpaired Individuals using GAMLSS: A Ethnic Comparison between Korean and Non-Hispanic White Cohorts

Presenter: Chun Min Young

Chun MIN YOUNG ¹, Sungjoo LEE ², Kim KYUNGA ³, Kim HEE JIN ⁴, Na DUK L. ⁴, Michael WEINER ⁵, Suzanne SCHINDLER ⁶, Kim JUN PYO ⁴, Seo SANG WON ⁴

¹Department of Neurology, Yonsei Severance Hospital, Yonsei University College of Medicine, Yonsei, Republic of Korea, ²Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Republic of Korea), Seoul, Republic of Korea, ³Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea,

⁴Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁵University of California, San Francisco, San Francisco, United States, ⁶Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States

00141 - Age-related blood CD8 T cells binding a non-self peptide/HLA epitope track with Alzheimer's and related MCI status in HLA-A2+ and HLA-A2- cohorts: expanding the reach of a T cell biomarker assay to all patients.

Presenter: Christopher Wheeler

Christopher WHEELER ^{1,2}, Debby VAN DAM ^{3,4}, Yannick VERMEIREN ^{3,4}, Hans DE REU ³, Peter Paul DE DEYN ^{3,4}

¹T-Neuro Pharma, Aptos, United States, ²Soc. for Brain Mapping & Therapeutics, Pacific Palisades, United States, ³University of Antwerp, Antwerp, Belgium, ⁴University of Groningen, Groningen, Netherlands

00137 - C2N Eligibility, APOE genotype Identification, Amyloid Confirmation. Results from the AHEAD 3-45 program at Neuroclin Glasgow

Presenter: Kanwal Aadil

Kanwal AADIL, Cowan LEWIS, Lynch JENNIFER, Inglis FRASER

¹NeuroClin Ltd, Motherwell, United Kingdom

00131 - The role of lipids on changes of plasma pTau181, pTau217 and the 217/181 ratio in Alzheimer's disease over time: a pilot study in a memory clinic population.

Presenter: Michaela DeFrancesco

Michaela DEFRANCESCO ¹, Alex HOFER ¹, Christian HUMPEL ¹

¹Innsbruck, Austria

00127 - Development and Evaluation of an MTBR Tau Fragment Immunoassay for the Assessment of Alzheimer's Disease Tau Pathology

Presenter: Shannon Leslie

Shannon LESLIE ¹, Setareh MOUGHADAM ¹, Kristof VAN KOLEN ², Gallen TRIANA-BALTZER ¹

¹Johnson and Johnson Innovative Medicine, San Diego, United States, ²Johnson and Johnson Innovative Medicine, Beerse, Belgium
Germain BUSTO

¹CMRR, Montpellier, France

00002 - Tau-Dependent Divergent Associations of Soluble and Plaque Amyloid with Glucose Dysregulation

Presenter: Dong Woo Kang

Dong Woo KANG ¹, Hyun Kook LIM ²

¹Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ²Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

00025 - A Correlation Between Plasma P-Tau181 Levels and Clinical Diagnosis of Alzheimer's Disease

Presenter: Anshu Arora

Aishwarya PRASAD ¹, Anshu ARORA ^{1,2}, Arun ARORA ¹, Mahima PATIL ¹, Arif KHAN ^{1,3}

¹Northwest Clinical Research Center, Bellevue, United States, ²Washington State University Elson S. Floyd College of Medicine, Spokane, United States, ³Pacific Northwest University of Health Sciences College of Osteopathic Medicine, Yakima, United States

05 • CLINICAL TRIALS: COGNITIVE AND FUNCTIONAL ENDPOINTS

00084 - Worse cognitive performance and poorer quality of life are associated with lower self-reported confidence in accomplishing personal priorities: the utility of the electronic Person Specific Outcome Measure (ePSOM) tool

Presenter: Ali Jannati

Stina SAUNDERS ^{1,2}, Claudio TORO-SEREY ¹, Ali JANNATI ^{1,3}, Sean TOBYNE ¹, Craig RITCHIE ⁴, Sarah GREGORY ⁴, Miles WELSTEAD ⁴, Álvaro PASCUAL-LEONE ^{1,3,5}

¹Linus Health, Boston, United States, ²University of Edinburgh, Edinburgh, United Kingdom, ³Department of Neurology, Harvard Medical School, Boston, United States, ⁴Scottish Brain Sciences, Edinburgh, United Kingdom, ⁵Marcus Institute for Aging Research and Wolk Center for Memory Health, Hebrew SeniorLife, Boston, United States

00239 - Four-Year Follow-Up of a Multimodal Intervention for Dementia Prevention: Extended Results from the J-MINT PRIME Tamba Randomized Controlled Trial

Presenter: Hisatomo Kowa

Hisatomo KOWA ¹, Tohmi OSAKI ², Ryoko KUMAGAI ¹, Yutaro OKI ¹

¹Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Kobe Gaukuin University, Faculty of Rehabilitation, Kobe, Japan

00241 - Comparing longitudinal trajectories of Storyteller and CDR-SB: Initial data from ADNI4

Presenter: Emil Fristed

Emil FRISTED ¹, Jack WESTON ¹, ADNI FOR THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE ²

¹Novoic Ltd, London, United Kingdom, ²ADNI, San Francisco, United Kingdom

00113 - Speed-Based Cognitive Training Improves Cholinergic Network Health: Implications for Cognitive Aging and Dementia Prevention from the INHANCE Randomized Clinical Trial

Presenter: Thomas Van Vleet

Thomas VAN VLEET ¹, Mouna ATTARHA ¹, Ana De Figueiredo PELEGRINO ², Paule-Joanne TOUSSAINT ², Sarah-Jane GRANT ¹, Lydia OUELLET ², Etienne DE VILLERS-SIDANI ²

¹Posit Science, San Francisco, United States, ²McGill University, Montreal, Canada

00006 - Evidence Supporting the Use of the Clinical Dementia Rating® as an Outcome Measure in Dementia with Lewy Bodies Clinical Trials

Presenter: James Galvin

James GALVIN, Andreas SALCEDO

¹University of Miami Miller School of Medicine, Boca Raton, United States

00251 - Regional Differences in the Presence of Data Quality Concerns in Dementia Clinical Trials

Presenter: David Miller

David MILLER ¹, Xingmei WANG ², Alan KOTT ³

¹Signant Health, Philadelphia, United States, ²Signant Health, Blue Bell, United States, ³Signant Health, Prague, Czech Republic

00126 - Comparative Sensitivity of MMSE, Resting-State EEG, and Event-Related Potentials in Longitudinal Cognitive Decline Detection

Presenter: Caroline Ma

Caroline MA ¹, Amir MEGHDADI ¹, Grant FOSTER ¹, Corinne FISCHER ², David SALAT ³, Chris BERKA ¹

¹Advanced Brain Monitoring, Inc., Carlsbad, United States, ²St. Michael's Hospital - Toronto (Canada), Toronto, Canada,

³Massachusetts General Hospital, Boston, United States

00210 - Memory support training and lifestyle modifications to promote healthy aging in persons at risk for Alzheimer's disease: Brain Boosters randomized controlled trial initial results

Presenter: Sarah Tomaszewski Farias

Sarah TOMASZEWSKI FARIAS ¹, Jaclyn FOX ¹, Hilary ARALIS ¹, Danielle HARVEY ¹, Michelle CHAN ¹, Michael RYAN ¹, Alyssa WEAKLEY ¹, Samina RAHMAN ², Catherine LUNA ², Maureen SCHMITTER-EDGEcombe ²

¹University of California, Davis, Sacramento, United States, ²Washington State University, Pullman, United States

00032 - Mediterranean Diet in Subjective Cognitive Decline: Cognitive, Mobility, and Neuroimaging Outcomes from a Randomized Cross-Over Trial

Presenter: Yu-Ruei Lin

Yu-Ruei LIN ¹, Li-Ning PENG ^{2,3}, Liang-Kung CHEN ^{2,3,4}, Chih-Ping CHUNG ^{1,5}

¹Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei City, Taiwan, Republic of China, ²Center for Geriatric and Gerontology, Taipei Veterans General Hospital, Taipei City, Taiwan, Republic of China, ³Center for Healthy Longevity and Aging Sciences, National Yang Ming Chiao Tung University, Taipei City, Taiwan, Republic of China, ⁴Taipei Municipal Gan-Dau Hospital (Managed by Taipei Veterans General Hospital), Taipei City, Taiwan, Republic of China, ⁵School of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan, Republic of China

00293 - The Efficacy and Safety of Mobile-App-Based Metamemory Cognitive Training for Mild Cognitive Impairment: A Multicenter, Randomized Clinical Trial

Presenter: Sunyoung Kang

Sunyoung KANG ^{1,2}, Jung-In LIM ³, Lukas STENZEL ⁴, Keun You KIM ¹, Eosu KIM ^{1,5,6}, Hong Jun JEON ⁷, Doo-Heum PARK ⁷, Hyun Kook LIM ^{8,9}, Yongsoo SHIM ¹⁰, Jae-Won JANG ¹¹, Yeshin KIM ¹¹, Kee Hyung PARK ¹²

¹Department of Psychiatry & Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ²Emocog Inc., Seoul, Republic of Korea, ³Interdisciplinary Program in Cognitive Science, Seoul, Republic of Korea, ⁴Cogthera GmbH, Munich, Germany, ⁵Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁶Metabolism-Dementia Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁷Department of Psychiatry, Konkuk University Medical Center, Seoul, Republic of Korea, ⁸Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ⁹CMC Institute for Basic Medical Science, the Catholic Medical Center of The Catholic University of Korea, Seoul, Republic of Korea, ¹⁰Department of Neurology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ¹¹Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Republic of Korea, ¹²Department of Neurology, College of Medicine, Gachon University, Gil Medical Center, Incheon, Republic of Korea

06 ● COGNITIVE ASSESSMENT AND CLINICAL TRIALS

00279 - ERP biomarkers of cognitive dysfunction in Alzheimer's disease: Real-world evidence for translation into clinical trial endpoints

Presenter: Amir Meghdadi

Amir MEGHDADI ¹, Natasha KOVACEVIC ¹, Chris BERKA ¹, Katy TARRIT MIRAKHORLI ², Shay NAKAHIRA ², Kirra BORRELLO ², Janette BOW-KEOLA ², Kylie YAMAUCHI ², Enrique CARRAZANA ², Janette ABRAMOWITZ ², Qi ZHI ³, Kore LIOW ²

¹Advanced Brain Monitoring, Carlsbad, United States, ²University of Hawaii, Honolulu, United States, ³Hawaii Pacific Neuroscience, Honolulu, United States

00270 - Integrating Plasma pTau-217 and Digital Cognitive Assessments for Early Detection in Alzheimer's Disease

Presenter: Casey Vanderlip

Casey VANDERLIP ¹, Craig STARK ¹

¹UC Irvine, Irvine, United States

00139 - Combining plasma pTau217 and a remote digital cognitive assessment to predict cognitive decline in cognitively unimpaired older adults

Presenter: Hairin Kim

Hairin KIM ¹, Daniel SOBERANES ¹, Roos JUTTEN ², Mark DUBBELMAN ¹, Gad MARSHALL ¹, Hyun-Sik YANG ¹, Dorene RENTZ ¹, Keith JOHNSON ³, Reisa SPERLING ³, Rebecca AMARIGLIO ¹, Kathryn PAPP ¹

¹Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States, Boston, United States,

²Department of Neurology, Amsterdam UMC location VUmc, Amsterdam, The Netherlands, Amsterdam, Netherlands, ³Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, Boston, United States

00214 - Speech-based digital cognitive assessments for scalable and cost-effective pre-screening of preclinical Alzheimer's Disease: Insights from the RETAIN study

Presenter: Anahita Kyani

Anahita KYANI ¹, Srinivasan VAIRAVAN ², Federico PARISI ³, Dzmitry KALIUKHOVICH ⁴, Macarena GARCIA VALDECASAS COLELL ⁵, Sara GALE ³, Bahador MARZBAN ³, Nicklas LINZ ⁶, Johannes TRÖGER ⁶, Janna HERRMANN ⁶, David HENLEY ², Fiona ELWOOD ³, Tricia THORNTON-WELLS ³, Bryan HANSEN ⁷, Lennert STEUKERS ⁴

¹Johnson & Johnson, La Jolla, United States, ²Johnson & Johnson, Titusville, United States, ³Johnson & Johnson, Cambridge, United States, ⁴Johnson & Johnson, Beerse, Belgium, ⁵Johnson & Johnson, Basel, Switzerland, ⁶ki elements GmbH, Saarbrücken, Germany, ⁷Johnson & Johnson, Spring House, United States

00175 - Electric Field of the Default Mode Network is Correlated with Effects of Transcranial Alternating Current Stimulation in Mild Alzheimer's Disease

Presenter: Aonan Li

Aonan LI ¹, Yi XING, Yi TANG ¹

¹Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, China

00024 - The validation of the new Chinese Short Cognitive Performance Test (SKT)

Presenter: Mark Stemmler

Mark STEMMLER ¹, Melina ARNOLD ¹, Liang CUI ², Qi-Hao GUO ²

¹University of Erlangen-Nuremberg, Erlangen, Germany, ²Shanghai Jiao Tong University School of Medicine, Shanghai, China

00262 - Interview Quality Matters: A Cross-Trial Analysis of CDR Administration Errors in Alzheimer's Disease Clinical Research

Presenter: Amanda Aedo

Amanda AEDO ¹, Gila BARBATI ¹, Sayaka MACHIZAWA ¹, Andrei IACOB ², Jessica STENCLIK ¹, Erica APPLEMAN ¹

¹Signant Health, Blue Bell, United States, ²Signant Health, Iasi, Romania

00244 - Linking the Mini-Mental State Examination and the 13-Item Version of Alzheimer's Disease Assessment Scale-Cognitive Subscale

Presenter: David Miller

David MILLER ¹, Alan KOTT ², Xingmei WANG ³

¹Signant Health, Philadelphia, United States, ²Signant Health, Prague, Czech Republic, ³Signant Health, Blue Bell, United States

00188 - Development and preliminary findings of the MoCA-Cognitive Health Questionnaire

Presenter: Ziad Nasreddine

Laura KLAMING ¹, Murray GILLIES ¹, Ziad NASREDDINE ¹

¹MoCA Cognition, Montreal, Canada

00013 - Cognitive Trajectories in Alzheimer's Disease: Findings from the Multinational CICERO-AD Chart Review Study

Presenter: Diego Novick

Diego NOVICK ¹, Giuseppe BRUNO ², Grazie DELL'AGNELLO ³, Anthony ZAGAR ⁴, Agota SZENDE ⁵, Victor KIRI ⁶, Mercè BOADA ⁷, Mercè BOADA ⁸

¹Eli Lilly and Company Ltd., Bracknell, United Kingdom, ²Department of Neurology and Psychiatry, University of Rome "Sapienza", Rome, Italy, ³Eli Lilly Italia Spa, Sesto Fiorentino, Italy, ⁴Eli Lilly and Company Ltd., Indianapolis, United States, ⁵Fortrea, York, United Kingdom, ⁶Fortrea, Maidenhead, United Kingdom, ⁷Ace Alzheimer Center Barcelona. Universitat Internacional de Catalunya, Barcelona, Spain, ⁸Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain

00066 - Automated linguistic and acoustic metrics of a smartphone-captured cued narration and recall assessment for detecting early memory and biomarker changes in early Alzheimer's disease

Presenter: Thanneer Perumal

Raphael ULLMANN ¹, Arnaud WOLFER ¹, Kami KOSEK ², Monika ZBYTNIIEWSKA-MÉGRET ³, Thanneer PERUMAL ¹, Irma KURNIAWAN ¹, Kirsten TAYLOR ¹

¹F. Hoffmann-La Roche Ltd., Basel, Switzerland, ²Roche Global IT Solution Center, Warsaw, Poland, ³CTC Resourcing Solutions AG, Basel, Switzerland

07 • BEHAVIORAL DISORDERS AND CLINICAL TRIALS

00009 - Pharmacological Class and Dose Effects on Neuropsychiatric Symptoms and Disease Severity in Dementia: A Defined Daily Dose-Based Cohort Study

Presenter: Jong-Ling Fuh

Yu-Ruei LIN, Jong-Ling FUH

¹Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China

08 • HEALTH ECONOMICS AND CLINICAL TRIALS

00159 - A Low-cost, Scalable Blood Biomarker Assay for Alzheimer's Disease Testing in Resource - Limited Settings

Presenter: Noah Elder

Robert LIN, Jason WAN, Noah ELDER, Hien NGUYEN, Paul HUNG

¹Taudia, San Carlos, United States

00042 - Economic value of a blood test for Alzheimer's disease pathology in primary and specialty care in the U.S.

Presenter: Soeren Mattke

Soeren MATTKE ¹, Jiahe CHEN ¹, Mark HANSON ¹, Kim JOHNSON ², Cara LEAHY ³, David MERRILL ⁴, Victoria SHADA ⁵, Jorge RUIZ ⁶

¹University of Southern California, Los Angeles, United States, ²Duke University, Durham, United States, ³Memorial Healthcare Institute, Owosso, United States, ⁴Pacific Brain Health Center, Santa Monica, United States, ⁵Wake Forest School of Medicine, Winston-Salem, United States, ⁶Memorial Healthcare System, Hollywood, United States

00171 - Enhancing Alzheimer's Disease Diagnostic Efficiency and Accuracy with Plasma-Based pTau217 Testing: A Comparative Analysis in Primary and Secondary Care

Presenter: Martin Guess

Sophie ROTH ¹, Martin GUESS ¹, Gustaf ORTSÄTER ²

¹Roche Diagnostics International, Rotkreuz Zg, Switzerland, ²Quantify Research AB, Stockholm, Sweden

00128 - Societal Cost and Efficiency Comparison of Subcutaneous vs Intravenous Lecanemab for Early Alzheimer's Disease in the United States

Presenter: Amir A. Tahami Monfared

Amir A. TAHAMI MONFARED ^{1,2}, Stephanie BARROWS ³, Lindsey FOX ³, Brittney HERBEL ³, William L. HERRING ^{3,4}, Alisha KRUMBACH ³, Quanwu ZHANG ¹

¹Eisai Inc., Nutley, United States, ²McGill University, Montreal, Canada, ³RTI Health Solutions, Durham, United States, ⁴Karolinska Institutet, Stockholm, Sweden

00047 - Medication Adherence and Cost of Care for Comorbid Conditions in Patients with Early Alzheimer's Disease: A Retrospective Cohort Study Using the Axon Registry and Claims Data

Presenter: Lei Lv

Lei LV ¹, Abdalla ALY ¹, Caroline MCKAY ¹, Paul MYSTKOWSKI ¹, Shannon GALLAGHER ², Kristian GARCIA ², Heather E. MOSS ³, Soeren MATTKE ⁴

¹Novo Nordisk Inc., Plainsboro, United States, ²Verana Health, New York, United States, ³Department of Ophthalmology, Stanford University & Department of Neurology & Neurological Sciences, Stanford University, Stanford, United States, ⁴University of Southern California, Los Angeles, United States

09 ● EPIDEMIOLOGY AND CLINICAL TRIALS

00281 - MCI Detection in Primary Care in the U.S.: Who is Finding the Cases?

Presenter: Ying Liu

Ying LIU, Wei YE, Andrew BECKER, Soeren MATTKE

¹University of Southern California, Los Angeles, United States

00277 - Odor Identification and Tau Burden in Persons without Dementia: Insights from the Mayo Clinic Study of Aging

Presenter: Mohamed Y. Elminawy

Mohamed Y. ELMINAWY ¹, Jeremiah A. AAKRE ², Jonathan GRAFF-RADFORD ¹, Prashanthi VEMURI ³, Christopher G. SCHWARZ ³, Walter K. KREMERS ², David S. KNOPMAN ¹, Val J. LOWE ³, Clifford R. JACK JR ³, Ronald C. PETERSEN ^{1,2}, Maria VASSILAKI ²

¹Department of Neurology, Mayo Clinic, Rochester, United States, ²Quantitative Health Sciences, Mayo Clinic, Rochester, United States,

³Department of Radiology, Mayo Clinic, Rochester, United States

00233 - Cross-Cohort Validation of Metabolomic Predictors of Global Cognition Using Elastic Net Regression

Presenter: Brandi Vollmer

Brandi VOLLMER ¹, Amaryllis SKYFA ², Christopher PAPANDREOU ², Christian HABECK ¹, Michal BEERI ³, Yaakov STERN ¹, Nikolaos SCARMEAS ¹, Yian GU ¹

¹Columbia University, New York, United States, ²Hellenic Mediterranean University, Chania, United States, ³Rutgers University, New Brunswick, United States

00259 - Sex/gender differences in the associations between parental education and hippocampal volume in the oldest-old: The Life After 90 Study

Presenter: Batool Rizvi

Batool RIZVI ¹, Paola GILSANZ ², Pauline MAILLARD ¹, Maria CORRADA ³, Rachel WHITMER ¹

¹UC Davis, Davis, United States, ²Kaiser Permanente Northern California Division of Research, Pleasanton, United States, ³UC Irvine, Irvine, United States

00243 - Associations between epigenetic and inflammatory aging, cognitive function, and blood-based biomarkers of Alzheimer's disease: cross-sectional and longitudinal findings from the INSPIRE-T cohort

Presenter: Laure Rouch

Samuel THURIOT, Jason SHOURICK, David FURMAN, Jean Marc LEMAITRE, Sophie GUYONNET, Bruno VELLAS, Sandrine ANDRIEU, Laure ROUCH

¹IHU HealthAge, Toulouse, France

00228 - Cardiorespiratory fitness and brain atrophy: Sex differences and potential vascular mechanisms.

Presenter: Adam J. Paulsen

Adam J. PAULSEN ^{1,2}, Ira DRISCOLL ^{1,2}, Brianne M. BREIDENBACH ^{1,2}, Matthew P. GLITTENBERG ^{1,2}, Sarah R. LOSE ^{1,2}, Yue MA ¹, Mark A. SAGER ¹, Catherine L. GALLAGHER ^{3,4}, Sanjay ASTHANA ^{1,2}, Sterling C. JOHNSON ^{1,2}, Bradley T. CHRISTIAN ⁵, Leonardo A. RIVERA-RIVERA ⁵, Oliver WIEBEN ^{5,6}, Dane B. COOK ^{7,8}, Ozioma C. OKONKWO ^{1,2}

¹Wisconsin Alzheimer's Disease Research Center, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, United States, ²Wisconsin Alzheimer's Institute, Madison, United States, ³Department of Neurology, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, United States, ⁴Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital, Madison, United States, ⁵Department of Medical Physics, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States, ⁶Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, United States, ⁷William S. Middleton Memorial Veterans Hospital, Madison, United States, ⁸Department of Kinesiology, University of Wisconsin School of Education, Madison, United States

00194 - ABIDEing with automated cerebrospinal fluid assays; update of an MCI to dementia prediction model

Presenter: Pieter Van Der Veere

Pieter VAN DER VEERE ¹, Argonde VAN HARTEN ¹, Stefanie VOS ², Pieter Jelle VISSER ², Sterling JOHNSON ³, Erik STORMRUD ⁴, Oskar HANSSON ⁴, Sebastian PALMQVIST ⁴, Gerard PIÑOL-RIPOLL ⁵, Hans BERKHOF ¹, Wiesje VAN DER FLIER ¹

¹Amsterdam UMC, Amsterdam, Netherlands, ²Maastricht University, Maastricht, Netherlands, ³University of Wisconsin-Madison, Madison, United States, ⁴Lund University, Malmo, Sweden, ⁵Hospital Universitari Santa Maria, Lleida, Spain

00195 - Real-world eligibility for lecanemab and donanemab based on Appropriate Use Recommendations in Korea

Presenter: So Yeon Jeon

So Yeon JEON ¹, Min Soo BYUN ², Hye Ji CHOI ³, Yoon Hee KIM ⁴, Chung Hee GWAG ⁵, Gijung JUNG ⁵, Dong Young LEE ⁵

¹SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ²Seoul National University College of Medicine, Seoul, Republic of Korea, ³Hallym University Dongtan Sacred Heart Hospital, Gyeonggi, Republic of Korea, ⁴Seoul National University Hospital, Seoul, Republic of Korea, ⁵Seoul National University Hospital, Seoul, Republic of Korea

00236 - Caregiving and Economic Burden of Alzheimer's Disease in Japan

Presenter: Quanwu Zhang

Ran GAO ¹, Kavita NAIR ², Brien SMITH ³, Babak HAJI ¹, Raymond ZHANG ¹, Noemi HUMMEL ⁴, Dave MORTON ⁵, Marta MARTINEZ ⁶, Stephanie READ ⁷, Quanwu ZHANG ¹, Amir Abbas TAHAMI MONFARED ¹

¹Eisai, Nutley, United States, ²University of Colorado Anschutz Medical Campus, Aurora, United States, ³Henry Ford Hospital, Detroit, United States, ⁴Certara GmbH, Loerrach, Germany, ⁵Certara, Princeton, United States, ⁶Certara, Madrid, Spain, ⁷Certara, Sheffield, United Kingdom

00208 - High Eligibility of Frail Older Adults with Early AD for Lecanemab Treatment in Real-World Practice: Is There a Need for New Clinical Trials?

Presenter: Federico Bellelli

Federico BELLELLI, Sandrine SOURDET, Gaelle SORIANO, Bruno VELLAS, Davide ANGIONI

¹Centre Hospitalo-Universitaire de Toulouse, Toulouse, France

00111 - Physician perception of treatment landscape and readiness in care delivery with anti-amyloid therapy for Alzheimer's disease in China

Presenter: Quanwu Zhang

Amir Abbas TAHAMI MONFARED ¹, Brien SMITH ², Kavita NAIR ³, Ran GAO ¹, Raymond ZHANG ¹, Babak HAJI ¹, Noemi HUMMEL ⁴, Agnieszka KOPIEC ⁵, Marta MARTINEZ ⁶, Stephanie READ ⁷, Quanwu ZHANG ¹

¹Eisai, Nutley, United States, ²Henry Ford Hospital, Detroit, United States, ³University of Colorado Anschutz Medical Campus, Aurora, United States, ⁴Certara, Loerrach, Germany, ⁵Certara, Krakow, Poland, ⁶Certara, Madrid, Spain, ⁷Certara, Sheffield, United Kingdom

10 ● ANIMAL MODEL AND PRECLINICAL TRIALS IN AD

00223 - TRIM21 mediated clearance of intracellular protein pathologies

Presenter: Rakez Kaye

Rakez KAYED

¹University of Texas Medical Branch, Galveston, United States

00076 - Fusing Transferrin Receptor Binders to the A β O-targeting Antibody Sabirnetug Achieves Increased Brain Penetration in Mice While Preserving Target Binding

Presenter: Elizabeth Johnson

Erika CLINE ¹, Shunsuke IIZUKA ², Mahiro KURODA ², Elizabeth JOHNSON ¹, Alex DAVIS ¹, Martin KLEINSCHMIDT ³, Oladayo OLADIRAN ⁴, Jennifer GILLIES ⁴, Jacob WOHLSTADTER ⁴, Thomas LAVOIE ¹, Liean SCHENCK ¹, Mathias SCHMIDT ², Hiroyuki SONODA ², Jasna JERECIC ¹, Paul SHUGHRUE ¹

¹Acumen Pharmaceuticals, Inc, Newton, Massachusetts, United States, ²JCR Pharmaceuticals Co., Ltd, Ashiya, Hyogo, Japan,

³Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany, ⁴Meso Scale Diagnostics, LLC, Rockville, Maryland, United States

00040 - APOE-Targeted Microglia-Specific Epigenome Therapy for Alzheimer's Disease

Presenter: Ornit Chiba-Falek

Boris KANTOR, Bernadette O'DONOVAN, Joseph RITTINER, Ornit CHIBA-FALEK

¹Duke University, Durham, United States

00250 - Administration of benzgalantamine, a galantamine prodrug, reduces multiple forms of hyperphosphorylated Tau and mitigates neuropathology in two animal models of traumatic brain injury: potential implication for reduced dementia risk.

Presenter: Denis Kay

Denis KAY ¹, Michael CHOPP ², Haiyan PANG ², Zheng Gang ZHANG ², Ye XIONG ², Abigail SCHINDLER ³, David COOK ³, James MEABON ⁴

¹Alpha Cognition Inc, Grapevine, United States, ²Henry Ford Health, Detroit, United States, ³VA Puget Sound, Seattle, United States,

⁴SIBCR, Seattle, United States

00150 - The APOE4 knock-in APP^{swe}/PSEN1dE9/Tau-P301S triple transgenic (E4-3Tg) mouse model exhibited Tak1–NF-κB-mediated astrocytic C3 overproduction, neurodegeneration and a severely reduced lifespan.

Presenter: Tatsuhiro Hisatsune

Chenxu LEI, Tatsuhiro HISATSUNE

¹The University of Tokyo, Kashiwa, Japan

00092 - A conditionally activated siRNA (CASI) targeting APOE for the treatment of Alzheimer's Disease

Presenter: Anindya Bhattacharya

Maxine NELSON, Akila RAM, Priya PULYA, Anna BADNER, Marina KOVALIOV, Clara TOURINO, Priyanka SINGH, Shilpi MAHAJAN, Lisa SCHERER, Don BUTTON, Robert DUFF, Dee DATTA, Charles ALLERSON, Anindya BHATTACHARYA

¹Switch Therapeutics, San Francisco, United States

00090 - A conditionally-activated siRNA targeting MAPT for the treatment of tauopathies

Presenter: Anindya Bhattacharya

Clara TOURINO, Marina KOVALIOV, Maxine NELSON, Priya PULYA, Shilpi MAHAJAN, Lisa SCHERER, Abhinav KUMAR, Don BUTTON, Robert DUFF, Dee DATTA, Charles Allerson CHARLES ALLERSON, Craig BLANCHETTE, Anindya BHATTACHARYA

¹Switch Therapeutics, San Francisco, United States

00112 - Antibody effector function of the murine analogue of Etalanetug drives efficacy in an animal model of pathological tau seeding and spreading

Presenter: Malcolm Roberts

Jane GARTLON, Sonia TALMA, Kavita MISTRY, Malcolm ROBERTS

¹Eisai Ltd., Hatfield, United Kingdom

00058 - SUVN-I6107, a True Positive Allosteric Modulator at Muscarinic M1 Receptor for Treatment of Cognitive Disorders, Update on the Development

Presenter: Vijay Benade

Vijay BENADE¹, Veera Raghava Chowdary PALACHARLA¹, Vinod Kumar GOYAL¹, Jyothsna RAVULA¹, Satish JETTA¹, Renny ABRAHAM¹, Rajeshbabu MEDAPATI¹, Ramkumar SUBRAMANIAN¹, Surendra PETLU¹, Anil SHINDE¹, Ilayaraja KALAIKADHIBAN¹, Ramakrishna NIROGI¹

¹Suven Life Sciences, Hyderabad, India

11 ● NEW THERAPIES AND CLINICAL TRIALS

00286 - Real-world treatment with lecanemab: medically significant and insignificant ARIA, and pseudo-ARIA.

Presenter: Lawrence Honig

Lawrence HONIG - ¹Columbia University, New York, United States

00260 - Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study

Presenter: Brian Rash

Brian RASH¹, John REEVES¹, Chris CONKLIN², Madhura INGALHALIKAR³, Nataliya AGAFONOVA¹, Joshua HARE¹

¹Longeveron INC, Miami, United States, ²Clario, Philadelphia, United States, ³Clario, Miami, United States

00249 - A Delphi panel exploring the burden of ARIA management from the provider's perspective

Presenter: Marwan Sabbagh

Marwan SABBAGH¹, Feride FRECH², Chenyue ZHAO², Hideki TOYOSAKI², Richard PERRY³, Medi STONE³, Sophie POPE³, Jerome BARAKOS⁴, Raymond TURNER⁵

¹Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, United States, ²Eisai, Inc., Nutley, New Jersey, United States, ³Adelphi Values PROVE, Bollington, Cheshire, United Kingdom, ⁴Sutter Health California Pacific Medical Center, San Francisco, California, United States, ⁵Department of Neurology, University of Georgetown, Washington, District Of Columbia, United States

00153 - Clinical trials (phases 1 & 2) of transdermal ALC919 peptide to activate brain mitochondrial complex I

Presenter: Sam Gandy

Sam GANDY¹, Toshiharu SUZUKI², Yasuomi OUCHI³, Hirotohi ADACHI⁴, Eugenii RABINER⁵, Manfred WINDISCH⁶, Mary SANO¹

¹Icahn School of Medicine at Mount Sinai, New York, United States, ²Hokkaido University & Tokyo Metropolitan University, Sapporo & Tokyo, Japan, ³Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁴PassPort Technologies, San Diego, United States, ⁵Perceptive Discovery, London, United Kingdom, ⁶NeuroScios, Graz, Austria

00246 - A Review of Patient Demographics, Clinical Characteristics, Eligibility, and Treatment Planning for lecanemab in an Academic Medical Center

Presenter: Nour Abi Chakra

Nour ABI CHAKRA¹, John DICKSON¹, Liliana RAMIREZ GOMEZ¹, Daniel SAUKKONEN¹, Michael ERKKINEN¹

¹Mass General Brigham, Boston, United States

00235 - MTX46943, a Novel TREM2 Small Molecule Agonist For The Treatment of Early-Stage Alzheimer 's Disease

Presenter: Niels Plath

Manuela POLYDORO¹, Ivana GERIC², Jin ZHENG¹, Tina SOMMER BISGAARD¹, Ashley COMER¹, Laura SANS¹, Joachim VILSTRUP¹, Leen WOLFS², Arya NAIR², Morten S. ANDERSEN¹, Ninna FREDERIKSEN¹, Peter FLAGSTAD¹, Maria DALBY¹, Rita BALICE-GORDON¹, Niels PLATH¹

¹Muna Therapeutics, Copenhagen, Denmark, ²Muna Therapeutics, Leuven, Belgium

00166 - International Registry for Alzheimer's Disease and Other Dementias (InRAD): design, data model, and interoperability

Presenter: Robert Perneczky

Casper DE BOER¹, Jean VONSY², Johan VAN BEEK², Robert HYDE², Chen WANG³, Giovanni FRISONI³, Wiesje VAN DER FLIER⁴, Jung-Lung HSU⁵, Frank JESSEN⁶, Robert PERNECZKY^{7,8,9}

¹Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands ²TW1 Healthcare Consulting Ltd, London, United Kingdom ³Memory Centre, Department of Rehabilitation and Geriatrics, Geneva University Hospitals; Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland ⁴Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands ⁵New Taipei Municipal TuCheng Hospital; President of the Taiwan Dementia Society, New Taipei City, Taiwan, Republic of China ⁶Department of Psychiatry and Psychotherapy, University of Cologne; German Centre for Neurodegenerative Diseases (DZNE) Cologne; Chair, European Alzheimer's Disease Consortium (EADC), Cologne, Germany ⁷Department of Psychiatry and Psychotherapy, LMU Hospital, Ludwig-Maximilians-Universität München, Munich, Germany; German Centre for Neurodegenerative Diseases (DZNE) Munich; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany ⁸Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, United Kingdom ⁹Division of Neuroscience, University of Sheffield, Sheffield, United Kingdom

00119 - Safety, Pharmacokinetics and Cardiodynamics of CMS121, a Novel Small Molecule Fisetin Derivative with Neuroprotective Properties, in Phase 1 Healthy Adult Volunteers

Presenter: Pamela Maher

Pamela MAHER¹, Ronald CHRISTOPHER², Rebecca EVANS², William RASCHKE²

¹Salk Institute, La Jolla, United States, ²Virogenics, San Diego, United States

00110 - Study Design in a Phase 2a Registration Trial for OAB-14 in the Treatment of Mild Cognitive Impairment (MCI) or Mild and Moderate Dementia due to Alzheimer's Disease

Presenter: Tang Yi

Tang YI¹, Zheng ZHONGHUI², Wang YIYUN²

¹Xuanwu Hospital Capital Medical University, Beijing, China, ²Shandong Xinhua Pharmaceutical Company Limited, Zibo, China

00046 - THN391 – A Novel, First-In-Class Anti-fibrin Antibody for Treatment of Inflammation in Alzheimer's Disease: An Ongoing Phase 1b Study for the Treatment of Early Alzheimer's Disease

Presenter: Brad Navia

Brad NAVIA¹, Aaron KANTOR¹, Tanja HOFFMAN¹, June KAPLOW¹, Henk MUTSAERTS², Frederik BARKHOF², Khalid ABD-ELAZIZ³, E. (Jort) VIJVERBEG², Catherine MUMMERY⁴, Craig RITCHIE⁵

¹Therini Bio, Sacramento, Ca, United States, ²Amsterdam UMC, Amsterdam, Netherlands, ³University Medical Center Groningen, Groningen, Netherlands, ⁴University College London Hospitals, London, United Kingdom, ⁵Scottish Brain Science, Edinburgh, United Kingdom

00010 - PNA5 For Treatment of Vascular Dementia: Composite Serum Biomarkers for VCID Patients Enrollment Stratification.

Presenter: Meredith Hay

Meredith HAY^{1,2,3}, Lee RYAN^{1,4}, Nancy SWEITZER⁵, Christina HOYER-KIMURA¹

¹University of Arizona, Tucson, United States, ²ProNeurogen, Inc, Tucson, United States, ³Evelyn F. McKnight Brain Institute, Tucson, United States, ⁴Evelyn F. McKnight Brain Institute, Tucson, United States, ⁵Washington University School of Medicine, St. Louis, United States

00292 - Region-Specific Effects of 40Hz Transcranial Current Stimulation (tACS) on EEG Activity in Patients with Mild Cognitive Impairment

Presenter: Do Hoon Kim

Do Hoon KIM¹

¹Department of Psychiatry, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Gangwon, Korea

00257 - Barriers to Current Anti-Amyloid β Infusion Therapies for Alzheimer's Disease and Preferences for Future Treatment: A Quantitative Survey

Presenter: Chad Swanson

Abigail SILBER¹, Amod ATHAVALE¹, Matthew O'HARA¹, Preeti S. BAJAJ², Chad SWANSON²

¹Trinity Life Sciences, Waltham, Ma, United States, ²Prothena Biosciences, Inc, Brisbane, Ca, United States

00221 - Design and Rationale for a Study to Evaluate Blood and Imaging Biomarkers of Personalized Neuromodulation Therapy of the Default Mode Network in patients with Alzheimer's Disease

Presenter: Lisa Fosdick

Lisa FOSDICK¹, Giacomo KOCH^{2,3}

¹Sinaptica Therapeutics, Cambridge, United States, ²Santa Lucia Foundation IRCCS, Rome, Italy, ³University of Ferrara, Ferrara, Italy

00229 - Evaluation of an ultra-high-frequency visual stimulation intervention on mild cognitive impairment and Alzheimer's Disease

Presenter: Julian Keil

Julian KEIL^{1,2,3}, Maria BUTHUT¹, Ravit HADAR³, Jana FASS⁴, Liam DOHERTY³, Jakob LITSCH³, Nikolett GAJDA³, Victor HERNANDEZ-URBINA³, Fabian QUEISNER³, Markus MÜSCHENICH³, Surjo SOEKADAR¹

¹Clinical Neurotechnology Lab, Department of Psychiatry and Neurosciences, Charité Campus Mitte (CCM), Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Potsdam Embodied Cognition Group, Department of Cognitive Science, University of Potsdam, Potsdam, Germany, ³Nuuron GmbH, Berlin, Germany, ⁴Medical School Berlin, Berlin, Germany

00064 - Phase 1, Multiple Ascending Dose Study of a Novel Orally Administered Mitochondria-Directed Drug Candidate (SUL-238) in Healthy Volunteers

Presenter: Nadir Ulu

Nadir ULU¹, Daniël H. SWART^{2,3}, Zafer SEZER^{4,5}, Ahmet INAL^{4,5}, Mustafa M. MAZICIOGLU⁶, Sedat ALTUG⁷, Serhat KOZLU¹, Adrianus C. VAN DER GRAAF³, Robert H. HENNING², Guido KRENNING^{2,3}, Murat EMRE⁸

¹Gen İlaç ve Sağlık Ürünleri A.Ş., Ankara, Türkiye, ²Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Sulfateq B.V., Groningen, Netherlands, ⁴Department of Pharmacology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye, ⁵Hakan Cetinsaya Good Clinical Practice and Research Centre (IKUM), Kayseri, Türkiye, ⁶Department of Family Medicine, Faculty of Medicine, Erciyes University, Kayseri, Türkiye, ⁷Department of Pharmacology, Faculty of Medicine, Demiroglu Bilim University, Istanbul, Türkiye, ⁸Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye

00067 - A First-in-Human, Single Dose-Escalation Study of CM383, a Novel Anti- Amyloid Beta antibody, in healthy volunteers

Presenter: Qing Wen

Kun HE¹, Cuigang LI¹, Yaoqi HAN¹, Yanshuang LI¹, Ning LI¹, Libo ZHANG², Zhichuan LI², Jingyue MA², Bo CHEN², Qing WEN¹

¹Jinan Central Hospital, Jinan, China, ²Keymed Biosciences (Chengdu) Co., Ltd - Chengdu, China

00057 - Masupirdine (A Pure 5-HT6 Receptor Antagonist): Update on the Phase-3 Clinical Study Targeting Agitation in Patients with Dementia of Alzheimer's Type

Presenter: Pradeep Jayarajan

Pradeep JAYARAJAN¹, Jyothsna RAVULA¹, Satish JETTA¹, Vinod Kumar GOYAL¹, Vijay BENADE¹, Anil SHINDE¹, Santosh Kumar PANDEY¹, Ramkumar SUBRAMANIAN¹, Abdul Rasheed MOHAMMED¹, Ramakrishna NIROGI¹

¹Suven Life Sciences Ltd, Hyderabad, India

12 ● PROOF OF CONCEPT FOR ALZHEIMER DRUG DEVELOPEMENT INTERVENTIONS

00276 - Optimized Delivery of Anti-Amyloid Therapeutics using Brain Shuttles against Novel Blood-Brain-Barrier Receptors

Presenter: Naveen Mehta

Naveen MEHTA¹, Alvaro GARCIA¹, Isabel ALBUJA¹, John AVERA¹, Alex REIS¹, Kimberly SCEARCE-LEVIE¹, Gleb KUZNETSOV¹, Pierce OGDEN¹

¹Manifold Bio, Boston, United States

00266 - Targeting of A β toxic oligomers via a designed peptide reduces plaque formation in an AD mouse model

Presenter: Carolyn Tallon

Carolyn TALLON¹, Sebastien PRADEL¹, Koya YAKABI¹, Emma BREYAK¹, Catalina PASCUALY¹, Chandresh GAJERA¹, Jeff POSAKONY¹, Gil BLOCK¹, Valerie DAGGETT¹

¹AltPep Corporation, Seattle, United States

00256 - A treatment management platform to enable safe, scalable deployment of disease-modifying therapies in Alzheimer's disease

Presenter: Adrián Noriega De La Colina

Adrián NORIEGA DE LA COLINA^{1,2,3}, Jorge J. LLIBRE-GUERRA⁴, Mario MASELLIS^{5,6}, Eric E. SMITH^{7,8}, Zahinoor ISMAIL^{7,8}, Nikolaos SCARMEAS^{9,10}, Sinjan GHOSH¹¹, Nilton CUSTODIO¹², Gerard PIÑOL-RIPOLL¹³, Paolo VITALI^{1,14}, Pedro ROSA-NETO^{1,15,2,16}, Mercè BOADA^{17,18}, Serge GAUTHIER^{1,19,20}, Christian DANSEREAU³, Andrew FRANK^{21,22}

¹Department of Neurology and Neurosurgery, McGill University, Montreal, Canada, ²Montreal Neurological Institute-Hospital, Montreal, Canada, ³Perceiv Research Inc., Montreal, Canada, ⁴Department of Neurology, Washington University in Saint Louis School of Medicine, Saint Louis, United States, ⁵Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada, ⁶Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada, ⁷Hotchkiss Brain Institute Cumming School of Medicine University of Calgary, Calgary, Canada, ⁸Department of Clinical Neurosciences Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁹1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University, Athens, Greece, ¹⁰Department of Neurology, The Gertrude H. Sergievsky Center, Taub Institute for Research in Alzheimer's Disease and the Aging Brain, New York, United States, ¹¹Narayana Health, Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, India, ¹²Instituto Peruano de Neurociencias, Lima, Peru, ¹³Unitat Trastorns Cognitius, Hospital Universitari Santa Maria, IRBLleida, Lleida, Spain, ¹⁴McGill University Research Centre for Studies in Aging, Douglas Research Institute - Montreal (Canada), Montreal, Canada, ¹⁵McGill University Research Centre for Studies in Aging, Douglas Research Institute, Montreal, Canada, ¹⁶The Peter O'Donnell Jr. Brain Institute (OBI), University of Texas Southwestern Medical Centre (UTSW), Dallas, United States, ¹⁷Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain, ¹⁸Networking Research Center On Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain, ¹⁹Department of Psychiatry, McGill University, Montreal, Canada, ²⁰McGill Dementia Education Program, Montreal, Canada, ²¹Bruyère Health Research Institute, Ottawa, Canada, ²²University of Ottawa, Ottawa, Canada

00061 - The brain permeable immunoproteasome-selective inhibitor AR-01 is a promising drug candidate for Alzheimer's disease

Presenter: Ji Eun Park

Ji Eun PARK¹, Til Bahadur THAPA MAGAR¹, Kyung Bo KIM^{1,2}

¹Center for Translational Science, Florida International University, Port St Lucie, United States, ²Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, United States

00100 - Efferocytosis-Driven Reduction of Neuroinflammation by Novel GAS6 Fusion Protein (GAIA) in Anti-A β Immunotherapies

Presenter: Jinkyung Lee

Soomin JI, Jinkyung LEE, Juho LEE, Sanghoon PARK

¹Illimis Therapeutics, Inc., Seoul, Republic of Korea

13 ● TRANSLATIONAL RESEARCH

00285 - The Global Neurodegeneration Proteomics Consortium (GNPC) V2: Expanding Real-World Proteomics to include lifestyle and drug interventions, additional geographies, and multiple proteomic platforms

Presenter: Farhad Imam

Farhad IMAM¹, Simon LOVESTONE², Krish VARSHA¹, Martin BRINGMANN²

¹Gates Ventures, Seattle, United States, ²Johnson & Johnson, London, United Kingdom

00271 - Translational Progress of NA-831, NA-911, and NA-931: Clinical Evidence Supporting a Unified Theory for Alzheimer's Disease, Stroke, and Obesity

Presenter: Lloyd Tran

Lloyd TRAN, Fern VU, Zung TRAN

Biomed Industries, Inc., San Jose, United States

00238 - Biallelic Human Genetic Background: Foundation for Divergent Pathomechanisms

Presenter: Kinga Szigeti

Kinga SZIGETI¹, Ivanna IHNATOVYCH¹, Nicolas ROSAS¹, Michael DWYER¹, Niels BERGSLAND¹, Ralph BENEDICT¹, Robert ZIVADINOV¹

¹University at Buffalo, Buffalo, United States

00031 - Exploration of Longitudinal Changes in Gut Microbiome Composition Stratified by Amyloid Status

Presenter: Jea Woo Kang

Jea Woo KANG¹, Rob KNIGHT², Rima KADDURAH-DAOUK³, Sterling C. JOHNSON¹, Sanjay ASTHANA¹, Cynthia M. CARLSSON¹, Nathaniel A. CHIN¹, Sandra HARDING¹, Kaj BLENNOW⁴, Henrik ZETTERBERG⁴, Tobey BETTHAUSER¹, Bradley CHRISTIAN¹, Tyler K. ULLAND⁵, Federico E. REY⁶, Barbara B. BENDLIN¹

¹Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, United States, ²Department of Pediatrics, University of California, San Diego, La Jolla, United States, ³Department of Psychiatry and Behavioral Sciences, Duke University, Durham, United States, ⁴Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, ⁵Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, United States, ⁶Department of Bacteriology, University of Wisconsin-Madison, Madison, United States

00134 - Associations Between Alzheimer's Disease and Stroke: Clinical Studies of NA-831 for AD and for Stroke

Presenter: Zung Tran

Lloyd TRAN¹, Fern VU¹, Zung TRAN¹

¹BioMed Industries, Inc., San Jose, United States

00130 - Associations Between Alzheimer's Disease and Obesity: Clinical Trials of NA-831 for AD and NA-931 for the Treatment of Obesity

Presenter: Zung Tran

Lloyd TRAN¹, Fern VU¹, Zung TRAN¹

¹Biomed Industries, Inc., San Jose, United States

00102 - TfR1-binding peptides to transport antibodies across blood brain barrier in cynomolgus monkeys

Presenter: Hao Wu

Hao WU, Xuefeng ZHANG¹, Yibo QIU¹, Fei SHENG¹, Yue WU¹

¹ChainGen Bio, Shanghai, China

00065 - Binding profiles of lecanemab and other amyloid-beta antibodies to amyloid-beta species isolated from Alzheimers's disease brain

Presenter: Lars Lannfelt

Lars LANNFELT ¹, Linda SÖDERBERG ², Malin JOHANNESSON ², Eleni GKANATSIU ², Nicolas FRITZ ², Charlotte SAHLIN ², Patrik NYGREN ², Olof ZACHRISSON ², Christer MÖLLER ²

¹Uppsala University, Uppsala, Sweden, ²BioArctic AB, Stockholm, Sweden

00045 - A diagnostic and prognostic plasma omics-biomarkers panel for Alzheimer's Disease based on microglial single-cell transcriptomics

Presenter: Ornit Chiba-Falek

Michael LUTZ, Ornit CHIBA-FALEK

¹Duke University, Durham, United States

00197 - Plasm p-tau217 predictive ability of Cognitive and Functional Decline in Non-demented Amyloid PET positive Older Individual: Three-year follow up data from Japanese Trial Ready cohort for preclinical and prodromal AD.

Presenter: Yoshiki Niimi

Yoshiki NIIMI ¹, Saki NAKASHIMA ¹, Kenichiro SATO ¹, Kensaku KASUGA ², Takeshi IKEUCHI ³, Takeshi IWATSUBO ⁴

¹The University of Tokyo Hospital, Tokyo, Japan, ²National Center for Geriatrics and Gerontology, Aichi, Japan, ³Niigata University, Niigata, Japan, ⁴National Center of Neurology and Psychiatry, Tokyo, Japan

00173 - Amyloid aggregation inhibition by physiological levels of dopamine: towards levodopa drug reformulation for correcting mild dopamine deficits and delaying Alzheimer's disease progression

Presenter: Joana Saavedra

Joana SAAVEDRA¹, Zsuzsa SÁRKÁNY¹, Isabel CARDOSO¹, Sandra MACEDO-RIBEIRO¹, Pedro M MARTINS¹

¹i3S, Porto, Portugal

00144 - Functional decline associated with all-cause mortality in patients with mild cognitive impairment and Alzheimer's dementia in real-world clinical practice

Presenter: Ying Wang

Peter MORIN ¹, Ying WANG ², Joel REISMAN ³, Dan BERLOWITZ ³, Donald MILLER ³, Wen HU ³, Shou-En LU ⁴, Raymond ZHANG ⁵, Amir Abbas TAHAMI MONFARED ⁵, Quanwu ZHANG ⁵, Weiming XIA ¹

¹Boston University, Boston, United States, ²Wentworth Institute of Technology, Boston, United States, ³University of Massachusetts, Lowell, United States, ⁴Rutgers University, Piscataway, United States, ⁵Eisai, Inc, Nutley, United States

00089 - Integrating Cognitive and Biological Signals in Early Alzheimer's: Predicting p217tau and MCI using the multi-modal Altoida NeuroMarker Platform

Presenter: Nicholas Griffin

Nicholas GRIFFIN ¹, Srinivasan VAIRAVAN ², Gallen TRIANA-BALTZER ³, Anahita KYANI ², Ziad SAAD ³, Meenakshi KHARE ⁴, Kara BARTONE ³, Silvia FALLONE ¹, Victoria BRUGADA-RAMENTOL ¹, M. Florencia IULITA ¹, Marc JONES ¹, Gayle WITTENBERG ², Emmanuel STREEL ¹

¹Altoida, Washington, Dc, United States, ²JNJ Innovative Medicine, Titusville, New Jersey, United States, ³JNJ Innovative Medicine, San Diego, California, United States, ⁴Quanterix, Billerica, Massachusetts, United States

14 ● BEYOND AMYLOID AND TAU

00264 - Development of Potent, Selective cPLA2 Inhibitors for Targeting Neuroinflammation in Alzheimer's Disease

Presenter: Amy Wang

Amy WANG ¹, Anastasiia SADYBEKOV ², Marlon DURO ², Xiaohui YU ², Stan LOUIE ², Shaowei WANG ², Vsevolod KATRITCH ², Hussein YASSINE ²

¹PebRx, Los Angeles, United States, ²USC, Los Angeles, United States

00068 - Misfolding of alpha-synuclein as a blood based fluid biomarker for Parkinson's disease

Presenter: Klaus Gerwert

Klaus GERWERT¹

¹Centre for Protein Diagnostics/Ruhr University Bochum, Bochum, Germany

00117 - Relationships between near end-of-life plasma biomarkers and postmortem cerebral and vascular amyloid, tau, TDP-43, and alpha-synuclein measurements

Presenter: Alpana Singh

Alpana SINGH¹, Marisa DENKINGER¹, Kewei CHEN², Kari DIECKHOFF¹, James LIU¹, Taina MARQUES¹, Geidy E. SERRANO¹, Thomas G. BEACH¹, Antoine LEUZY¹, Alireza ATRI¹, Eric M. REIMAN², Nicholas J. ASHTON^{2,1}

¹Banner Health, Sun City, United States, ²Banner Alzheimer's Institute, Phoenix, United States

00203 - Fanning the flames: Did COVID-19 accelerate progression of Alzheimer's disease in the ADNI cohort?

Presenter: Patricia Andrews

Patricia ANDREWS, Ke XU, Kiara BAKER, Kathleen MATHER, Brian BOYD, Hakmook KANG, Warren TAYLOR, Paul NEWBOUSE

¹Vanderbilt University Medical Center, Nashville, United States

00190 - Degenerative Pathologies on Cortical Biopsy, Dopaminergic Depletion, and Shunt Efficacy in iNPH

Presenter: Byoung Seok Ye

Minsun CHOI^{1,2}, Su-Hee JEON¹, Sohyeon LEE¹, Yeoju KIM¹, Byoung Seok YE^{1,2}

¹Yonsei University College of Medicine, Seoul, Republic of Korea, ²Metabolism-Dementia Research Institute, Seoul, Republic of Korea

00093 - Perceptions of and Engagement in Brain Health Activities Among Middle-Aged and Older Adults: Associations with Level of Concern, Family History of Dementia, Subjective Memory Loss, and Demographics

Presenter: Raymond L. Ownby

Raymond L. OWNBY¹, Gesulla CAVANAUGH¹, Shannon WEATHERLEY¹, Shazia AKHTARULLAH¹, Joshua CABALLERO²

¹Nova Southeastern University, Fort Lauderdale, United States, ²University of Georgia, Athens, United States

00004 - Early microglial activation and astrogliosis in preclinical Alzheimer's disease

Presenter: Marta Fernández-Matarrubia

Marta FERNÁNDEZ-MATARRUBIA¹, Andrea VALERA-BARRERO², Mónica RENUNCIO-GARCÍA³, Marcos AGUILELLA⁴, Carmen LAGE¹, Gonzalo OCEJO-VIÑALS³, Sara LÓPEZ-GARCÍA¹, Francisco MARTÍNEZ-DUBARBIE¹, Ana POZUETA-CANTUDO⁴, María GARCÍA-MARTÍNEZ⁴, María BRAVO⁴, Andrea CORRALES-PARDO⁴, Juan IRURE-VENTURA³, Pascual SÁNCHEZ-JUAN⁵, Eloy RODRÍGUEZ-RODRÍGUEZ⁶

¹Neurology Service, Marqués de Valdecilla University Hospital; Institute for Research Marqués de Valdecilla (IDIVAL), Santander, Spain; CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Institute of Health Carlos III, Madrid, Spain ²Neurology Service, Marqués de Valdecilla University Hospital, Santander, Spain ³Institute for Research Marqués de Valdecilla (IDIVAL); Immunology Department, Marqués de Valdecilla University Hospital, Santander, Spain ⁴Neurology Service, Marqués de Valdecilla University Hospital; Institute for Research Marqués de Valdecilla (IDIVAL), Santander, Spain ⁵Institute for Research Marqués de Valdecilla (IDIVAL), Santander, Spain; Alzheimer's Centre Reina Sofía – CIEN Foundation – ISCIII, Madrid, Spain ⁶Neurology Service, Marqués de Valdecilla University Hospital; Institute for Research Marqués de Valdecilla (IDIVAL); Medicine and Psychiatry Department, University of Cantabria, Santander, Spain

15 ● CLINICAL TRIALS EARLY CAREER INVESTIGATOR SHOWCASE

00282 - Plasma and CSF proteomic signatures of lifestyle activities: a search for biomarkers of cognitive reserve in the Stanford Aging and Memory Study (SAMS)

Presenter: Irina Skylar-Scott

Olivia LU¹, Patricia MORAN LOSADA¹, Amelia FARINAS¹, Veronica BOT¹, Daisy DING¹, Zihuai HE¹, Valerie CARR², Hillary VOSSLER¹, Jennifer PARK¹, Sharon SHA¹, Tony WYSS-CORAY¹, Elizabeth MORMINO¹, Anthony WAGNER¹, Irina SKYLAR-SCOTT¹

¹Stanford University, Palo Alto, United States, ²San Jose State University, San Jose, United States

00269 - Testing and Tailoring Group Cognitive Behavioral Therapy for Insomnia (CBTi) with Persons with Early-Stage Alzheimer's disease and their Care Partners

Presenter: Inga Antonsdottir

Inga ANTONSDOTTIR, Molly ATWOOD, Constantine LYKETSOS

¹Johns Hopkins School of Medicine, Baltimore, United States

00118 - MRI utilization for ARIA response in patients receiving lecanemab

Presenter: Giovanna Pilonieta

Giovanna PILONIETA ^{1,2}, Karen FAHNESTOCK ¹, Christina MAMAEVA ¹, Laurie MORRISON ¹, Danielle WILLS ¹, Maria PISU ^{3,4}, David GELDMACHER ^{1,5}

¹Division of Cognitive and Behavioral Neurology, Birmingham, United States, ²Alzheimer's Disease Center - Birmingham (United States), Birmingham, United States, ³Division of General Internal Medicine & Population Science, Birmingham, United States, ⁴Alzheimer's Disease Center, Birmingham, United States, ⁵Alzheimer's Disease Center, Birmingham, United States

00115 - Feasibility and accuracy of the LILA app: Pilot study of a fully remote, self-administered, verbal list learning task for community cognitive screening

Presenter: Karra D. Harrington

Karra D. HARRINGTON ¹, Jess SEGURA ¹, Shannon ARCHER ¹, Laura MILLER ¹, Ruth RAY ¹, Najeeba FAROUK ¹, Anders NORDBLOM ², Sophia LERDAHL ², Kaycee M. SINK ¹, Pam VENTOLA ¹

¹Cogstate Ltd, New Haven, United States, ²Asteroida Ventures LLC, DBA Formative, Seattle, United States

00033 - A preliminary study on the effectiveness of therapeutic agricultural programs for healthy individuals and patients with dementia

Presenter: Bon D. Ku

Bon D. KU ¹, Boram KIM ², Nayeon LEE ², Hong Mo KU ³, Jeon YESEO ⁴

¹Department of Neurology, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Republic of Korea, ²GyeYang Mubicipal Dementia Daycare Center, Incheon, Republic of Korea, ³Institute for Cognitive Intervention, International St. Mary's Hospital, Incheon, Republic of Korea, ⁴Incheon Metropolitan City Agricultural Technology Center, Incheon, Republic of Korea

00029 - Broad Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus in Alzheimer's Disease: A Rationale, Study Design, and Preliminary Open-Label Data

Presenter: Michael Leuchter

Michael LEUCHTER ¹, Hanadi OUGHLI ¹, Kelly DURBIN ¹, Nicholas JACKSON ¹, David ELASHOFF ¹, Timothy CHANG ¹, Juliana CORLIER ¹, Cole MATTHEWS ¹, Julia SUN ¹, Darice WONG ¹, Brent FOGEL ¹, Andrew LEUCHTER ¹, Keith VOSSEL ¹, Nanthia SUTHANA ²

¹UCLA, Los Angeles, United States, ²Duke, Durham, United States

16 ● DIGITAL HEALTH/ E-TRIALS

00136 - Validating a Multi-Domain Digital Endpoint Platform (NeuLogiq) for Decentralized Alzheimer's Trials: Results from the CNS-101 Study

Presenter: Brian Murphy

Brian MURPHY ¹, Alison BUICK ², Shannon DIGGIN ², Ruth MCKERNAN ³, James B. ROWE ⁴, Laura RUEDA-DELGADO ¹

¹Cumulus Neuroscience, Dublin, Ireland, ²Cumulus Neuroscience, Belfast, United Kingdom, ³Dementia Discovery Fund, London, United Kingdom, ⁴Cambridge University, Cambridge, United Kingdom

00051 - Double XpressO: repeated online prescreening of cognitive impairment

Presenter: Willem Huijbers

Willem HUIJBERS ¹, Hans-Aloys WISCHMANN ², Kacylia PISTOIA ³, Joana KRIEGER ³, Johanna GRUBER ³, Murray GILLIES ¹, Ziad NASREDDINE ³

¹MoCA Cognition, Eindhoven, Netherlands, ²Charite, Berlin, Germany, ³MoCA Cognition, Montreal, Canada

00199 - Adherence to a multi-domain, person-centered, dementia risk factor management intervention to prevent cognitive decline (The BetterBrains Trial)

Presenter: Yen Ying Lim

Emily ROSENICH¹, Darshini AYTON¹, Stephanie PIROTTA¹, Hannah CUMMINS¹, Samantha DE ARAUGO¹, Amelia BEVINS¹, Catherine ROBB¹, Paul MARUFF², Yen Ying LIM¹

¹Monash University, Melbourne, Australia, ²Cogstate Ltd., Melbourne, Australia

00109 - A Holistic Approach for Understanding Alzheimer's Disease via Wearables, Speech, and eCOA

Presenter: Kevin Machado Gamboa

Kevin MACHADO GAMBOA¹, Brett MEYER², Paul O'DONOHUE¹

¹Medidata, London, United Kingdom, ²Medidata, Vermont, United Kingdom

00091 - Impact of Telemedicine on Time and Process Measures Associated with Detection and Diagnosis of Alzheimer's Disease

Presenter: Eric Klein

Eric KLEIN¹, Eric ANDERSON², Chad PANNUCCI¹, Jiaying GUO¹, Aadrika AADRIKA¹, Bert VARGAS¹, Julie BEYERER¹

¹Eli Lilly and Company, Indianapolis, United States, ²Syanpticture, Chicago, United States

00039 - A Digital Olfactory Biomarker Platform for Prognostic Enrichment of Neurodegeneration

Presenter: Subhanjan Mondal

Subhanjan MONDAL¹, Sara MOUSTAFA², Levi MUYELA³, Anne GITERE³, Anne NYAMBURA³, Karen BLACKMON³, Farooq WAHEED¹, Mie RIZIG⁴, Mohamed SALAMA², Irene MEIER⁵, Vaibhav NARAYAN⁵

¹Sensify Inc, New York, United States, ²Institute of Global health and Human Ecology, American University at Cairo, Egypt, ³Brain and Mind Institute, Aga Khan University Nairobi, Kenya, ⁴UCL Queen Square Institute of Neurology, London, United Kingdom, ⁵Davos Alzheimer's Collaborative, Geneva, Switzerland

00220 - In-Air-Time during Drawing Tests as a Potential Predictor of Amyloid Positivity in Mild Cognitive Impairment Patients

Presenter: Ko Woon Kim

Ko Woon KIM^{1,2}, Byoung-Soo SHIN³

¹Beth Israel Hospital, Harvard Medical School, Boston, United States, ²Jeonbuk National University Medical School and Hospital, Jeonju, Republic of Korea, ³Jeonbuk National University Medical School and Hospital, Jeonju, Republic of Korea

00216 - Real-World Care of Alzheimer's Disease Patients (n=2,358) in Germany: Insights from Registry of the Neurologists Network NeuroTransData (NTD) using the Physician/Patient Platform (DESTINY)

Presenter: Arnfin Bergmann

Arnfin BERGMANN¹, Stefan BRAUNE¹, Oliver FASOLD¹, Niloofar TAVAKOLI¹, Ntd STUDY GROUP¹

¹NeuroTransData GmbH, NTD Study Group, Neuburg an der Donau, Neuburg, Germany

00094 - Leveraging the FTD Disorders Registry to Enhance Clinical Trial Recruitment in Frontotemporal Degeneration

Presenter: Shana Dodge

Mary KRAUSE¹, Carrie MILLIARD², Reinecker ROBERT³, Sweatha REDDY⁴, Shana DODGE⁵, Penny DACKS⁶

¹FTD Disorders Registry, Norristown, United States, ²FTD Disorders Registry, Scarborough, United States, ³FTD Disorders Registry, Myrtle Beach, United States, ⁴FTD Disorders Registry, Jessup, United States, ⁵Association for Frontotemporal Degeneration, Philadelphia, United States, ⁶Association for Frontotemporal Degeneration, Brecksville, United States

00055 - Exploring Persona-Based Large Language Model Simulation for Social Surveys on Dementia Treatment

Presenter: Kenichiro Sato

Kenichiro SATO¹, Yoshiki NIIMI¹, Saki NAKASHIMA¹, Ryoko IHARA², Kazushi SUZUKI³, Atsushi IWATA², Takeshi IWATSUBO¹

¹The University of Tokyo Hospital, Tokyo, Japan, ²Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ³National Defense Medical College, Saitama, Japan

00063 - Preliminary Efficacy of the Healthy Actions and Lifestyles to Avoid Dementia (HALT-AD) Program for Enhancing Dementia-Risk Knowledge, Self-Efficacy, and Diet Quality in Primary-Care Patients

Presenter: Sarah Banks

Sarah BANKS¹, Sara MOUKARZEL¹, Ashley ROBLES¹, Ammar MANDVI¹, Breanna HOLLOWAY¹, Jordan STIVER¹

¹UC San Diego, San Diego, United States

17 ● ARTIFICIAL INTELLIGENCE IN AD CLINICAL TRIALS

00182 - AI+MRI imaging biomarker for clinical characterization of Alzheimer's disease biological heterogeneity

Presenter: Joon-Kyung Seong

Tae Youn KWON¹, Yeong-Hun JEON¹, Yeong-Hun SONG¹, Wha Jin LEE¹, Joon-Kyung SEONG¹, Jeong-Yeon SONG¹

¹Neuroxt, Seoul, Republic of Korea

00273 - Simulating cognitive decline using generative AI model

Presenter: Joon-Kyung Seong

Yeong-Hun SONG^{1,2}, Youn Kwon TAE^{1,2}, Wha Jin LEE², Joon-Kyung SEONG^{1,3,2}

¹Department of Artificial Intelligence, College of Informatics, Korea University, Seoul, Republic of Korea, ²NeuroXT, Seoul, Republic of Korea, ³School of Biomedical Engineering, College of Health Science, Korea University, Seoul, Republic of Korea

00106 - Post hoc data-driven subgroup analysis of the A4 Study: spatiotemporal atrophy predicts differential treatment response to solanezumab

Presenter: Neil Oxtoby

Cameron SHAND^{1,2,3}, An ZHAO^{1,2}, Pawel MARKIEWICZ^{1,4}, Gonzalo CASTRO LEAL^{1,2}, David CASH^{1,5}, Daniel ALEXANDER^{1,2}, Michael DONOHUE⁶, Frederik BARKHOF^{1,7,8}, Neil OXTOBY^{1,2}

¹UCL Hawkes Institute, University College London, London, United Kingdom, ²Department of Computer Science, University College London, London, United Kingdom, ³Crick Institute, London, United Kingdom, ⁴Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom, ⁵Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom, ⁶Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, United States, ⁷UCL Queen Square Institute Of Neurology, University College London, London, United Kingdom, ⁸Amsterdam University Medical Center, Amsterdam, Netherlands

00116 - Identifying and mitigating site-level data integrity risks in Alzheimer's trials using subject-level heuristics and a novel machine learning framework

Presenter: Joseph Geraci

Joseph GERACI^{1,2,3,4}, Christian CUMBAA¹, Bessi QORRI¹, Larry ALPHS¹, Luca PANI^{5,6}, Patrick O'KEEFE⁷, Suzanne HENDRIX⁷

¹NetraMark Corp., Toronto, Canada, ²Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada, ³Arthur C. Clarke Centre for Human Imagination, School of Physical Sciences, University of California, San Diego, La Jolla, United States, ⁴Tandem Centre for Pharmacogenetics, Molecular Brain Science Department, Centre for Addiction and Mental Health, Toronto, Canada, ⁵Department of Psychiatry and Behavioral Sciences, Leonard M. Miller School of Medicine, University of Miami, Coral Gables, United States, ⁶Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, ⁷Pentara Corporation, Salt Lake City, United States

00071 - Speech Biomarker for Cognition and Correlation with Clinical Outcome Measures Over Time in Preclinical Alzheimer's Disease

Presenter: Alexandra König

Alexandra KÖNIG¹, Elisa MALLICK¹, Johannes TRÖGER¹, Oriol GRAU-RIVERA², Andreea RADOI², Claudia PORTA-MAS²

¹ki:elements, Saarbrücken, Germany, ²Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain

00070 - Development of a Community-Based Predictive Model for Mild Cognitive Impairment Using Digital Clock Drawing and Complex Figure Tests

Presenter: Ruochen Li

Xiaonan ZHANG¹, Ruochen LI², Yang LI¹

¹First Hospital of Shanxi Medical University, Taiyuan, China, ²University of California, Davis, United States

00248 - Assessing variability in brain segmentation across multiple recent automated methods

Presenter: Luc Bracoud

Cheng C.J. CHU ^{1,2}, Thomas CAJGFINGER ¹, Joël SCHAËRER ³, Po-Han CHEN ⁴, Janos SZALMA ⁵, Chris CONKLIN ⁶, Madhura INGALHALIKAR ⁶, David SCOTT ⁶, Alessandro DELMONTE ¹, Luc BRACOUUD ¹

¹Clario, Lyon, France, ²Wistron ITS, Taipei, Taiwan, Republic of China, ³Clario, Geneva, Switzerland, ⁴Clario, Estenfeld, Germany, ⁵Clario, Budapest, Hungary, ⁶Clario, Philadelphia, United States

00242 - Improving FreeSurfer robustness by integrating automated failure detection using Artificial Intelligence for consistent quantitative biomarker extraction

Presenter: Luc Bracoud

Thomas CAJGFINGER ¹, Alessandro DELMONTE ¹, Joël SCHAËRER ², Po-Han CHEN ³, Joonmi OH ⁴, Qui CAO ⁴, Madhura INGALHALIKAR ⁴, Chris CONKLIN ⁴, David SCOTT ⁴, Luc BRACOUUD ¹

¹Clario, Lyon, France, ²Clario, Geneva, Switzerland, ³Clario, Estenfeld, Germany, ⁴Clario, Philadelphia, United States

00085 - Large Language Models for Clinical Dementia Rating Severity Assessment: Domain-Specific Performance Analysis

Presenter: Hahyun Lee

Hahyun LEE ^{1,2}, Da Young OH ^{1,3}, Jun-Young LEE ^{1,2,3}

¹Department of Psychiatry, Seoul Metropolitan Government-Seoul National University College Boramae Medical Center, Seoul, Republic of Korea, ²Interdisciplinary Program in Cognitive Science, Seoul National University, , Seoul, Republic of Korea, ³Department of Biomedical Sciences, Seoul National University, Seoul, Republic of Korea

00043 - Tracking Cognitive Change over Time Using a Remote Telephone-Based AI-Driven Digital Cognitive Assessment

Presenter: Alexandra König

Elisa MALLICK ¹, Johannes TRÖGER ¹, Stefanie KÖHLER ², Alexandra KÖNIG ³, Anika WUESTEFELD ⁴, Erik STOMRUD ⁴, Pontus TIDEMAN ⁴, Oskar HANSSON ⁴, Sebastian PALMQVIST ⁴, Stefan TEIPEL ², Nicklas LINZ ¹

¹ki elements GmbH - Saarbrücken (Germany), ²German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany, ³ki elements GmbH, Saarbrücken, Germany, ⁴Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden



Keep in touch! Follow Us on Social Media



LinkedIn

CTAD Alzheimer



X #CTAD25

@CTADConference

ctad@ant-congres.com

www.ctad-alzheimer.com